

10/730,643

FILE 'HOME' ENTERED AT 09:00:10 ON 28 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:00:17 ON 28 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

DICTIONARY FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

\*\*\* YOU HAVE NEW MAIL \*\*\*

=>


Uploading C:\Program Files\Stnexp\Queries\10730643.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 09:00:37 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 2211 TO ITERATE

100.0% PROCESSED 2211 ITERATIONS  
SEARCH TIME: 00.00.01

1171 ANSWERS

L2 1171 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 09:00:43 ON 28 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Dec 2004 VOL 142 ISS 1

FILE LAST UPDATED: 24 Dec 2004 (20041224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d 19 bib abs hitstr 1-15

L9 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2000:31284 CAPLUS  
DN 132:78806  
TI Oligonucleotide-polyamide conjugates for use as PCR primers and  
hybridization probes  
IN Tregear, Geoffrey William; Haralambidis, Jim  
PA Howard Florey Institute of Experimental Physiology and Medicine, Australia  
SO U.S., 22 pp., Cont.-in-part of U.S. 5,552,540.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6013434	A	20000111	US 1995-343535	19950209
	US 5552540	A	19960903	US 1993-68604	19930527
	WO 9324511	A1	19931209	WO 1993-AU252	19930528 <--

W: AU, JP, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI	US 1989-457747	B1	19891222
	AU 1992-2682	A	19920529
	US 1993-68604	A2	19930527
	WO 1993-AU252	W	19930528
	AU 1987-2666	A	19870624
	US 1993-477995	A2	19930424

AB This invention relates to novel oligonucleotide-polyamide conjugates preferably having a free 3'-hydroxyl moiety, and wherein the polyamide is coupled to the oligonucleotide through its carboxyl terminus. Nucleotide polymer conjugates Nu-NUC-C.tplbond.C-X1-NH-X2-X3 [X1 is an unsubstituted or substituted C1-C10 alkylene group, in which one or more carbons may optionally be replaced by -NH-, -O- or -S-; X2 is a bond, or an unsubstituted or substituted C1-C20 alkylene group, in which one or more carbons may optionally be replaced by -NH-, -O- or -S-; X3 is an amino acid, or a polyamide linked via its carboxy terminus; NUC is a nucleoside group; Nu is an oligonucleotide] are reported. Methods of preparing these compds., and various uses, for example, as PCR primers, or as a substrate for DNA or RNA polymerase, are also disclosed.

IT **146954-81-6DP**, controlled-pore glass-bound **146954-81-6P**  
**146954-82-7DP**, controlled-pore glass-bound **146954-82-7P**  
**146954-88-3DP**, controlled-pore glass-bound


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oligonucleotide-polyamide conjugates for use as PCR primers and hybridization probes)

RN 146954-81-6 CAPLUS

CN Carbamic acid, [3-[1-[2-deoxy-5-O-(9-phenyl-9H-xanthen-9-yl)- $\beta$ -D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146954-81-6 CAPLUS

CN Carbamic acid, [3-[1-[2-deoxy-5-O-(9-phenyl-9H-xanthen-9-yl)-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146954-82-7 CAPLUS

CN Uridine, 2'-deoxy-5'-O-(9-phenyl-9H-xanthen-9-yl)-5-[3-[(9-phenyl-9H-xanthen-9-yl)amino]-1-propynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 146954-82-7 CAPLUS

CN Uridine, 2'-deoxy-5'-O-(9-phenyl-9H-xanthen-9-yl)-5-[3-[(9-phenyl-9H-xanthen-9-yl)amino]-1-propynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 146954-88-3 CAPLUS

CN Carbamic acid, [6-[[3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-(3-carboxy-1-oxopropyl)-2-deoxy-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]amino]-6-oxohexyl]-, mono(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






IT 146954-80-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(oligonucleotide-polyamide conjugates for use as PCR primers and hybridization probes)

RN 146954-80-5 CAPLUS

CN Carbamic acid, [3-[1-[2-deoxy-5-O-(9-phenyl-9H-xanthen-9-yl)-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:650367 CAPLUS

DN 119:250367

TI Zwitterionic DNA

AU Hashimoto, Hiromasa; Nelson, Marek G.; Switzer, Christopher

CS Dep. Chem., Univ. California, Riverside, CA, 92521, USA  
SO Journal of the American Chemical Society (1993), 115(16),  
7128-34  
CODEN: JACSAT; ISSN: 0002-7863

DT Journal  
LA English

AB As a strategy to make DNA net charge neutral, oligodeoxyribonucleotides bearing pyrimidine 5- $\omega$ -aminohexyl substituents have been synthesized and characterized. The resultant zwitterionic oligomers bind to the natural DNA at low ionic strength as well or better than does natural DNA with itself, even when all of the nucleotides in a given single strand are rendered zwitterionic. As would be expected, stabilities of duplexes bearing zwitterionic strands are relatively insensitive to changes in solution ionic strength as compared with natural DNA. Somewhat surprising, however, is the finding that a DNA duplex composed of a fully zwitterionic strand and a natural complementary strand exhibits no change in stability over a 20-fold change in ionic strength. Thus, double- and single-stranded states in this case have equivalent charge densities, consistent with the zwitterionic strand contributing no net charge. Stabilization due to the ammonium ions was verified by comparing free energies of DNA duplexes bearing hexyl tethered ammonium ions with those bearing simply hexyl groups devoid of ammonium ions. This comparison showed that without an added pos. ammonium ion, the hexyl tether itself has a severe and cumulative unfavorable effect on duplex stability. Finally, zwitterionic nucleotides are found to distinguish matched from mismatched nucleotides in cDNA strands to a degree that rivals natural DNA.


IT 149798-20-9P 149798-21-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrogenation of)

RN 149798-20-9 CAPLUS

CN Uridine, 2'-deoxy-5-[6-[(trifluoroacetyl)amino]-1-hexynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 149798-21-0 CAPLUS

CN Cytidine, 2'-deoxy-5-[6-[(trifluoroacetyl)amino]-1-hexynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1993:597261 CAPLUS

DN 119:197261

TI Method for preparing probes for nucleic acid identification

IN Takenishi, Soichiro; Suzuki, Osamu; Yokomizo, Hirohiko; Shoji, Tomotoshi; Ooyama, Akihiro; Ishimaru, Mika

PA Nisshin Spinning, Japan

SO Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05184395	A2	19930727	JP 1992-26217	19920116 <--
PRAI	JP 1992-26217		19920116		
OS	MARPAT 119:197261				

AB The method comprises enzyme polymerization of the functional group-containing derivs.

of nucleoside triphosphate, and incorporation of label through functional group binding for preparing probe for DNA determination The nucleoside triphosphate

derivs. contain nitro, sulfonyl, amino, hydroxy, mercapto, carboxy, aldehyde, etc. Thus, 5-(3-aminopropyl)cytidine-5'-triphosphate was used for preparing fluorescein-label RNA probe for mouse NFG gene.

5-(3-Aminopropyl)-2'-deoxyuridine-5'-triphosphate was used for preparing DNA probe.

IT 150718-26-6P


RL: PREP (Preparation)

(preparation of RNA probe with)

RN 150718-26-6 CAPLUS

CN Cytidine 5'-(tetrahydrogen triphosphate), 5-(3-amino-1-propynyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.





L9 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1993:118248 CAPLUS  
 DN 118:118248  
 TI **Nucleic acid** sequence analysis with  
 nucleoside-5'-O-(1-thiotriphosphates)  
 IN Lee, Linda J.  
 PA Applied Biosystems, Inc., USA  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9206219	A1	19920416	WO 1991-US7345	19910927 <--
	W: JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	US 5187085	A	19930216	US 1990-590218	19900928 <--
	EP 550646	A1	19930714	EP 1991-918268	19910927 <--
	EP 550646	B1	20000405		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05507000	T2	19931014	JP 1991-517034	19910927 <--
	JP 06061280	B4	19940817		
	AT 191511	E	20000415	AT 1991-918268	19910927
PRAI	US 1990-590218	A	19900928		
	WO 1991-US7345	W	19910927		


AB A chain-terminating method of **nucleic acid** sequencing  
 in which comprises an oligonucleotide primer is extended with a  
**nucleic acid** polymerase in a reaction mixture containing  
 nucleoside-5'-O-(1-thiotriphosphate) precursors and  $\geq 1$   
 chain-terminating nucleotide is described. The resulting DNA fragment  
 products have more uniform bands as seen after electrophoresis and  
 therefore give more accurate base determination Preparation of  
 chain-terminating  
 dideoxynucleotides labeled with different dyes selected from rhodamines  
 and fluoresceins was shown. Sequence determination using rhodamine-labeled  
 dideoxynucleotides, nucleoside-5'-O-(1-thiotriphosphate) precursors, and  
 Sequenase (a T7 DNA polymerase) in a Mn<sup>++</sup>-containing buffer was also  
 described.

IT **142975-54-0D**, conjugate with dideoxynucleosides  
**142975-63-1D**, conjugate with dideoxynucleosides  
 RL: USES (Uses)  
 (in DNA sequencing by chain termination, nucleoside thiotriphosphates  
 for improved band uniformity and accuracy in)  
 RN 142975-54-0 CAPLUS  
 CN Uridine 5'-(tetrahydrogen triphosphate), 2',3'-dideoxy-5-[3-[[[(3',6'-  
 dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-6-  
 yl)carbonyl]amino]-1-propynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

HO—



PAGE 1-B




RN 142975-63-1 CAPLUS


CN Cytidine 5'-(tetrahydrogen triphosphate), 2',3'-dideoxy-5-[3-[[ (2',7'-dichloro-3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)carbonyl]amino]-1-propynyl]- (9CI) (CA INDEX NAME)

PAGE 1-A

HO—




PAGE 1-B



IT 143600-87-7P  
 RL: PREP (Preparation)  
 (preparation of, for DNA sequencing by chain termination, nucleoside  
 thiotriphosphates in, for improved band uniformity and accuracy in)  
 RN 143600-87-7 CAPLUS  
 CN Xanthylum, 9-[2-[[[3-[4-amino-1,2-dihydro-2-oxo-1-[tetrahydro-5-(3,5,7,7-  
 tetrahydroxy-3,5,7-trioxido-2,4,6-trioxa-3,5,7-triphosphahept-1-yl)-2-  
 furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]-6-carboxyphenyl]-3,6-  
 bis(ethylamino)-, chloride, (2R-cis)- (9CI) (CA INDEX NAME)


PAGE 1-A



EtNH

● Cl<sup>-</sup>

PAGE 1-B



L9 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1991:627790 CAPLUS  
 DN 115:227790  
 TI Spectrally resolvable rhodamine dyes for **nucleic acid**  
 sequence determination  
 IN Bergot, John B.; Chakerian, Vergine; Connell, Charles R.; Eadie, J. Scott;  
 Fung, Steven; Hershey, Davis N.; Lee, Linda G.; Menchen, Steven M.; Woo,  
 Sam L.  
 PA Applied Biosystems, Inc., USA  
 SO PCT Int. Appl., 29 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9105060	A2	19910418	WO 1990-US5565	19900927 <--
	WO 9105060	A3	19910516		
	W: JP				

RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE  
 US 5366860 A 19941122 US 1989-415050 19890929  
 EP 496749 A1 19920805 EP 1990-914874 19900927 <--  
 EP 496749 B1 19951206  
 R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE  
 JP 05502371 T2 19930428 JP 1990-513838 19900927 <--  
 JP 2649102 B2 19970903  
 AT 131210 E 19951215 AT 1990-914874 19900927  
 PRAI US 1989-415050 A 19890929  
 WO 1990-US5565 W 19900927

OS MARPAT 115:227790

AB A spectrally resolvable set of rhodamine dyes are provided for use in the chain termination method of **nucleic acid** sequencing.

A different rhodamine dye from the group consisting of tetramethylrhodamine, rhodamine X, rhodamine 6G, and rhodamine 110 is attached to the base of each of the dideoxynucleotides used in the sequencing method by way of an alkynylamino linker. Preferably, the labeled dideoxynucleotides are incorporated into the growing DNA chains by Taq DNA polymerase. The preferred 3'-terminal dideoxynucleotides for labeling for use in sequencing are 2',3'-dideoxy-7-deazaadenosine, 2',3'-dideoxycytidine, 2',3'-dideoxy-7-deazainosine, 2',3'-dideoxy-7-deazaguanosine and 2',3'-dideoxyuridine. Use of the labeled dideoxynucleotides in an automated sequencer identified >450 bases of M13 plasmid DNA.

IT 136977-17-8 136977-21-4 136977-25-8  
 136977-29-2 136977-35-0 136977-41-8  
 137004-07-0

RL: ANST (Analytical study)  
 (as dye for DNA sequencing)

RN 136977-17-8 CAPLUS


CN Xanthylium, 9-[2-carboxy-6-[[[3-[1,2,3,4-tetrahydro-2,4-dioxo-1-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]phenyl]-3,6-bis(dimethylamino)-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 136977-16-7

CMF C37 H36 N5 O8


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2



RN 136977-21-4 CAPLUS


CN Xanthylium, 9-[5-[[[3-[4-amino-1,2-dihydro-2-oxo-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]-2-(ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethyl-, (2R-cis)-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 136977-20-3

CMF C41 H45 N6 O7


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2



RN 136977-25-8 CAPLUS

CN Xanthylium, 3,6-diamino-9-[5-[[[3-[6-amino-1,2-dihydro-2-oxo-3-[(2R,5s)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-pyrimidinyl]-2-


propynyl]amino]carbonyl]-2-carboxyphenyl]-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 136977-24-7

CMF C33 H29 N6 O7


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2



RN 136977-29-2 CAPLUS


CN Xanthylum, 9-[2-(ethoxycarbonyl)-5-[[[3-[1,2,3,4-tetrahydro-2,4-dioxo-1-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]phenyl]-3,6-bis(ethylamino)-2-methyl-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 136977-28-1

CMF C40 H42 N5 O8


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2



RN 136977-35-0 CAPLUS


CN Xanthylium, 9-[2-[[[3-[4-amino-1,2-dihydro-2-oxo-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]-6-carboxyphenyl]-3,6-bis(dimethylamino)-, (2R-cis)-, acetate (salt) (9CI)  
(CA INDEX NAME)

CM 1

CRN 136977-34-9

CMF C37 H37 N6 O7


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2



RN 136977-41-8 CAPLUS


CN Xanthylum, 3,6-diamino-9-[2-carboxy-5-[[[3-[1,2,3,4-tetrahydro-2,4-dioxo-1-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]phenyl]-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 136977-40-7

CMF C33 H28 N5 O8

Absolute stereochemistry.






CM 2

CRN 71-50-1

CMF C2 H3 O2



RN 137004-07-0 CAPLUS


CN Xanthylum, 9-[2-[[[3-[4-amino-1,2-dihydro-2-oxo-1-[tetrahydro-5-(hydroxymethyl)-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]-6-carboxyphenyl]-3,6-bis(ethylamino)-, (2R-cis)-, acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 137004-06-9

CMF C37 H37 N6 O7


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2



IT 136977-52-1P 136977-55-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as dye for DNA sequencing)

RN 136977-52-1 CAPLUS


CN Xanthylum, 9-[2-[[[3-[4-amino-1,2-dihydro-2-oxo-1-[tetrahydro-5-[(phosphonooxy)methyl]-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]-6-carboxyphenyl]-3,6-bis(ethylamino)-, (2R-cis)-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 136977-51-0

CMF C37 H38 N6 O10 P


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2



RN 136977-55-4 CAPLUS


CN Xanthylum, 9-[2-carboxy-6-[[[3-[1,2,3,4-tetrahydro-2,4-dioxo-1-[tetrahydro-5-[(phosphonooxy)methyl]-2-furanyl]-5-pyrimidinyl]-2-propynyl]amino]carbonyl]phenyl]-3,6-bis(dimethylamino)-, (2R-cis)-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 136977-54-3

CMF C37 H37 N5 O11 P


Absolute stereochemistry.



CM 2

CRN 71-50-1

CMF C2 H3 O2




IT 136977-58-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with rhodamine X ester)

RN 136977-58-7 CAPLUS

CN 5'-Cytidylic acid, 5-(3-amino-1-propynyl)-2',3'-dideoxy- (9CI) (CA INDEX NAME)




IT 136977-56-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with tetramethylrhodamine ester)

RN 136977-56-5 CAPLUS

CN 5'-Uridylic acid, 5-(3-amino-1-propynyl)-2',3'-dideoxy- (9CI) (CA INDEX NAME)



L9 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:409259 CAPLUS

DN 115:9259

TI Preparation of crosslinking oligonucleotides as **nucleic acid** hybridization probes

IN Petrie, Charles R.; Meyer, Richard B.; Tabone, John C.; Hurst, Gerald D.

PA Microprobe Corp., USA

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9014353	A1	19901129	WO 1990-US2740	19900515 <--
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	EP 472648	A1	19920304	EP 1990-908844	19900515 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				

JP 04507402	T2	19921224	JP 1990-508242	19900515 <--
US 5824796	A	19981020	US 1994-334490	19941104
US 38416	E	20040203	US 2000-693213	20001019

PRAI US 1989-353857 A 19890518  
US 1988-250474 B2 19880928  
WO 1990-US2740 W 19900515  
US 1993-49807 B1 19930420  
US 1994-334490 A5 19941104

OS MARPAT 115:9259


AB R1-B-(CH2)q-Yr-(CH2)m-Al [R1 = H, sugar (analog) moiety optionally containing Q1, Q2, Q3, P, etc.; Q1 = OH, OP(O)(OH)2, OP(O)(OH)OP(O)(OH)2; Q2 = O, S; Q3 = CH2R2, SR2, OR2, NR2R3; R2, R3 = H, alkyl; B = **nucleic acid** base or an analog thereof; Y = functional linking group; m, q = 0, 1-8 integer; r = 0, 1; Al = leaving group], useful as **nucleic acid** hybridization probes and therefore useful for diagnosis of diseases, were prepared Reaction of 5-iodo-2'-deoxyuridine in DMF with 4-phthalimido-1-butyne in the presence of (Ph3P)4Pd and Et3N at 60° for 3 h gave 5-(4-phthalimido-1-butyne-1-yl)-2'-deoxyuridine, whose hydrogenation over Raney Ni gave 5-(4-phthalimidobutyl)-2'-deoxyuridine. 5-[3-(Trifluoroacetamido)propyl]-2'-deoxyuridine was prepared similarly and converted according to known methods into 5'-O-(dimethoxytrityl)-2'-deoxyuridine-3'-(N,N-diisopropyl)phosphoramidite cyanoethyl ester, which was used in the automated synthesis of 3'-CT TCC U1TG TAG CTG-5' [I; U1 = 5-(3-aminopropyl)-2'-deoxyuridine residue]. This was reacted with N-(iodoacetoxy)succinimide to give II [U1 = 5-(3-iodoacetamidopropyl)-2'-uridine residue], whose crosslinking to a 30-mer oligonucleotide derived from human papillomavirus (HPV) was evaluated.

IT **134140-85-5P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrogenation of)

RN 134140-85-5 CAPLUS

CN Uridine, 2'-deoxy-5-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)-1-butyrynyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1990:631903 CAPLUS  
DN 113:231903  
TI **Nucleic acid** related compounds. 59. Solvent, not palladium oxidation state, is the primary determinant for successful coupling of terminal alkynes with idonucleosides  
AU Robins, Morris J.; Vinayak, Ravi S.; Wood, Steven G.  
CS Dep. Chem., Brigham Young Univ., Provo, UT, 84602, USA

SO Tetrahedron Letters (1990), 31(26), 3731-4

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

OS CASREACT 113:231903

AB Coupling of iodo nucleosides with terminal alkynes such as 3-(acylamino)propynes, whose initial products readily undergo secondary cyclization reactions, can be effected smoothly by the standard catalysis with Pd(PPh<sub>3</sub>)<sub>4</sub> or (Ph<sub>3</sub>P)<sub>2</sub>PdCl<sub>2</sub>/CuI/Et<sub>3</sub>N in DMF.


IT 114748-60-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 114748-60-6 CAPLUS

CN Uridine, 2',3'-dideoxy-5-[3-[(trifluoroacetyl)amino]-1-propynyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




IT 114748-58-2P 130532-28-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, by alkynylation of iodo analog, DMF as solvent in)

RN 114748-58-2 CAPLUS

CN Cytidine, 2',3'-dideoxy-5-[3-[(trifluoroacetyl)amino]-1-propynyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.




RN 130532-28-4 CAPLUS

CN Benzoic acid, 4-methyl-, [tetrahydro-5-[4-hydroxy-2-oxo-5-[3-[(trifluoroacetyl)amino]-1-propynyl]-1(2H)-pyrimidinyl]-2-furanyl]methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L9 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1990:515768 CAPLUS  
 DN 113:115768  
 TI DNA dynamics from a spin probe: dependence of probe motion on tether length  
 AU Kirchner, James J.; Hustedt, Eric J.; Robinson, Bruce H.; Hopkins, Paul B.  
 CS Dep. Chem., Univ. Washington, Seattle, WA, 98195, USA  
 SO Tetrahedron Letters (1990), 31(5), 593-6  
 CODEN: TELEAY; ISSN: 0040-4039  
 DT Journal  
 LA English  
 OS CASREACT 113:115768  
 GI



I

AB The phosphoramidite I [R = C(C6H4OMe-p)2Ph, R1 = P(OCH2CH2CN)N(CHMe2), n = 2] (II) a spin labeled analog of thymidine, was synthesized and incorporated into the deoxyoligonucleotide 5'-d(CGCGAATT\*CGCG) (T\* = spin-labeled phosphoramidite II). This substance adopts a duplex structure, as shown by gel electrophoretic mobility. The ESR spectrum of the spin labeled duplex in solution was indicative of subnanosecond probe motion, a result which contrasts with the ca. 5 ns correlation time determined for the corresponding analog I (n = 1) (III). Steric inhibition of rotation of the nitroxide-bearing ring of III not present in nucleic acid containing II accounts for this difference.  
 IT 129077-26-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and dimethoxytritylation and phosphitylation of)  
 RN 129077-26-5 CAPLUS  
 CN 1H-Pyrrol-1-yloxy, 3-[4-[1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-1,3-butadiynyl]-2,5-dihydro-2,2,5,5-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 129077-27-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and incorporation of, into deoxyoligonucleotide, in study of DNA dynamics)

RN 129077-27-6 CAPLUS

CN 1H-Pyrrrol-1-yloxy, 3-[4-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-2-deoxy-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-1,3-butadiynyl]-2,5-dihydro-2,2,5,5-tetramethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OMe

L9 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1990:213554 CAPLUS  
DN 112:213554  
TI Mobility-shifting analog for differentiation of **nucleic acid** segments on the basis of nucleotide differences  
IN Kornher, John S.; Livak, Kenneth J.  
PA du Pont de Nemours, E. I., and Co., USA  
SO U.S., 10 pp.  
CODEN: USXXAM  
DT Patent  
LA English

## FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4879214	A	19891107	US 1988-272068	19881115 <--
	EP 369360	A2	19900523	EP 1989-120944	19891111 <--
	EP 369360	A3	19910109		
	R: BE, DE, FR, GB, IT, NL, SE				
	DK 8905699	A	19900516	DK 1989-5699	19891114 <--
	JP 02231099	A2	19900913	JP 1989-294099	19891114 <--
	CA 2003038	AA	19900515	CA 1989-2003038	19891115 <--
PRAI	US 1988-272068	A	19881115		
GI					



AB A process for distinguishing **nucleic acid** segments on the basis of nucleotide differences comprises (1) synthesizing complementary **nucleic acid** strands on each of  $\geq 2$  target **nucleic acid** templates with a **nucleic acid** polymerase and nucleoside triphosphate substrates, where  $\geq 1$  of the natural nucleoside triphosphate substrates is completely replaced by a mobility-shifting analog; (2) if necessary, denaturing the synthesized strands from the templates; and (3) comparing the mobility of the sep. synthesized strands in a single-stranded form with a size-fractionation medium. Thus, the mobility shifting analog I was synthesized from 5-(3-amino-1-propynyl)-2'-deoxycytidine-5'-triphosphate (preparation given) and Na sulfosuccinimidyl 6-(biotinamido)hexanoate. I was used in primer extension anal. to compare segments of 2 alleles of the human insulin receptor gene differing by a single nucleotide substitution. Polymerase chain reactions were used to amplify a 140-base pair region of DNA encoding the above receptor from 2 individuals, 1 homozygous and 1 heterozygous for deoxycytidine at position 2143. The amplified templates were hybridized with a 20-base pair primer.



A primer extension reaction was then performed, using dATP, dGTP, dUTP, and I or dCTP as substrate. Electrophoretic separation of the primer extension products demonstrated electrophoretic mobility shifts when I was substituted for dCTP in the extension reaction. Incorporation of I allowed for the discrimination of 2 templates from the same individual that differed by a single deoxycytidine substitution.

IT 126786-05-8

RL: ANST (Analytical study)

(as mobility-shifting analog, **nucleic acid**

differentiation using primer extension reaction with)

RN 126786-05-8 CAPLUS


CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-5-[3-[[6-[[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]amino]-1-oxohexyl]amino]-1-propynyl]-, [3aS-(3a $\alpha$ ,4 $\beta$ ,6a $\alpha$ )]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 124607-57-4

CMF C28 H44 N7 O16 P3 S

PAGE 1-A




PAGE 2-A




CM 2

CRN 121-44-8  
CMF C6 H15 N




L9 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1989:574570 CAPLUS  
DN 111:174570  
TI Palladium-catalyzed synthesis of alkynylamino nucleosides. A universal linker for nucleic acids  
AU Hobbs, Frank W., Jr.  
CS Cent. Res. Dev. Dep., E. I. Dupont de Nemours and Co., Wilmington, DE, 19898, USA  
SO Journal of Organic Chemistry (1989), 54(14), 3420-2  
CODEN: JOCEAH; ISSN: 0022-3263  
DT Journal  
LA English  
OS CASREACT 111:174570  
AB A method for attaching alkynylamino linkers to nucleosides and nucleotides is described. Protected or unprotected alkynylamines are coupled to iodo nucleosides in DMF using Pd(PPh<sub>3</sub>)<sub>4</sub>-CuI (1:2), a catalyst system superior to the standard Pd(II) species. The resulting alkynylamino nucleosides are useful for enzymic or chemical labeling of all four bases of DNA.  
IT **114748-58-2P 114748-60-6P 115899-38-2P**  
**115899-40-6P 115899-42-8P 115899-44-0P**  
**115899-45-1P 115899-46-2P 120609-05-4P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 114748-58-2 CAPLUS  
CN Cytidine, 2',3'-dideoxy-5-[3-[(trifluoroacetyl)amino]-1-propynyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 114748-60-6 CAPLUS  
CN Uridine, 2',3'-dideoxy-5-[3-[(trifluoroacetyl)amino]-1-propynyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 115899-38-2 CAPLUS  
 CN Cytidine, 2'-deoxy-5-[3-[(trifluoroacetyl)amino]-1-propynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 115899-40-6 CAPLUS  
 CN Uridine, 2'-deoxy-5-[3-[(trifluoroacetyl)amino]-1-propynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 115899-42-8 CAPLUS  
 CN Uridine, 2',3'-dideoxy-5-[5-[(trifluoroacetyl)amino]-1-pentynyl]- (9CI) (CA INDEX NAME)




RN 115899-44-0 CAPLUS

CN Uridine, 2',3'-dideoxy-5-[12-[(trifluoroacetyl)amino]-1-dodecynyl]- (9CI)  
(CA INDEX NAME)



RN 115899-45-1 CAPLUS


CN Uridine, 5-(5-amino-1-pentynyl)-2',3'-dideoxy- (9CI) (CA INDEX NAME)



RN 115899-46-2 CAPLUS

CN Uridine, 5-(3-amino-1-propynyl)-2',3'-dideoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 120609-05-4 CAPLUS


CN Uridine, 5-[3-[(trifluoroacetyl)amino]-1-propynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1989:439836 CAPLUS  
 DN 111:39836  
 TI Preparation of 5-(3-aminoprop-1-ynyl)deoxyuridine derivatives and their  
 use for synthesis of DNA and RNA labeled with nonradioactive markers.  
 IN Haralambidis, Jim  
 PA Florey, Howard, Institute of Experimental Physiology and Medicine,  
 Australia  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8810264	A1	19881229	WO 1988-AU207	19880624 <--
	W: AU, JP, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8819909	A1	19890119	AU 1988-19909	19880624 <--
	AU 598946	B2	19900705		
	EP 366685	A1	19900509	EP 1988-905594	19880624 <--
	EP 366685	B1	19941019		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02504144	T2	19901129	JP 1988-505657	19880624 <--
	JP 2828642	B2	19981125		
	CA 1340032	A1	19980908	CA 1988-570427	19880624
PRAI	AU 1987-2666	A	19870624		
	WO 1988-AU207	A	19880624		
OS	MARPAT 111:39836				
GI					



AB The title nucleoside derivs. [I; Y = H, (un)protected OH; X = H, phosphonate group, P(OQ)NR1R2; R1, R2 = (un)branched, (un)substituted alkyl; Q = phosphate protecting group; Z = H, phosphate, triphosphate group; X1 = (un)branched (1-15 alkyl; R = amino protecting group, A, Y1NHA; A = fluorophore (e.g. fluorescein) or other non-radioactive detectable group (e.g. biotin, avidin, colloidal Au or Ag, ferritin, and enzymes such as  $\beta$ -galactosidase, urease, peroxidase);  $\gamma$ 1 = (un)branched C1-10 alkylcarbonyl], useful for preparing DNA and RNA labeled with non-radioactive detectable markers as **nucleic acid** hybridization probes, were prepared. Thus, coupling of 3',5'-di-O-p-toluoyl-5-iododeoxyuridine with BOCNHCH2C.tplbond.CH (BOC = CO2CMe3) in EtOAc in the presence of (Ph3P)2PdCl2, CuI and Et3N gave 84% I (Y = H, Z = X = toluoyl, X1NHR = C .tplbond. CCH2NHGBOC). Saponification of the latter with

K2CO3 in MeOH followed by reaction with 4,4'-dimethoxytrityl chloride (DMTrCl) in pyridine gave 68% I (X = Y = H, Z = DMTr, X1NHR = C.tplbond.CCH2NHBOC) which was treated with [(Me2CH)2N]2POMe in CH2Cl2 containing tetrazole and (Me2CH)2NH to give I [Y = H, Z = CMTr, X = P(OMe)N(CHMe2)2, X1NHR = C.tplbond.CCH2NHBOC]. The latter can be reacted by the phosphoramidite method to prepare oligonucleotides which incorporate the modified nucleoside on the 5'-end or internally.

IT **114079-33-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and acylation of, with nitrophenylaminohexanoate derivative)

RN 114079-33-3 CAPLUS


CN Uridine, 5-(3-amino-1-propynyl)-2'-deoxy-, 3',5'-bis(4-methylbenzoate), mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 114079-32-2

CMF C28 H27 N3 O7


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 114079-31-1P 114079-35-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and condensation of, with bis(diisopropylamino)methoxyphosphine)

RN 114079-31-1 CAPLUS

CN Carbamic acid, [3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy- $\beta$ -D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 114079-35-5 CAPLUS

CN Carbamic acid, [6-[[3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy- $\beta$ -D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A



IT 114079-29-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

```
(preparation and reaction of, in preparation of nucleic acid
marker)
```

RN 114079-29-7 CAPLUS

CN Carbamic acid, [3-[1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 114079-34-4P



RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and saponification-alkylation of, by dimethoxytrityl chloride)

RN 114079-34-4 CAPLUS

CN Carbamic acid, [6-[[[3-[1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.







IT 114079-36-6P 114103-42-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for nonradioactive marker-labeled  
oligonucleotides)

RN 114079-36-6 CAPLUS

CN Carbamic acid, [6-[[3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-  
[[bis(1-methylethyl)amino]methoxyphosphino]-2-deoxy-β-D-erythro-  
pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-  
propynyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 114103-42-3 CAPLUS


CN Carbamic acid, [3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-[[bis(1-methylethyl)amino]methoxyphosphino]-2-deoxy-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




DN 108:187182  
 TI Preparation of base-modified nucleosides suitable for non-radioactive label attachment and their incorporation into synthetic oligodeoxyribonucleotides  
 AU Haralambidis, Jim; Chai, Miao; Tregear, Geoffrey W.  
 CS Howard Florey Inst. Exp. Physiol. Med., Univ. Melbourne, Parkville, 3052, Australia  
 SO Nucleic Acids Research (1987), 15(12), 4857-76  
 CODEN: NARHAD; ISSN: 0305-1048  
 DT Journal  
 LA English  
 OS CASREACT 108:187182  
 AB A very mild and efficient procedure has been developed for the preparation of C-5 substituted deoxyuridines. The substituent carries a masked primary aliphatic amino group. These compds. are readily converted into their phosphoramidites and can be used to prepare oligonucleotides carrying one or more aliphatic amino groups. Fluorescein isothiocyanate coupled to these compds. gives oligonucleotide probes carrying multiple fluorescein labels. These compds. have a free 5'-hydroxy group enabling additional 5'- end radioactive labeling for evaluation of their hybridization characteristics. Oligonucleotides carrying a long (11 atom) linker arm to the fluorescein hybridize more efficiently to mRNA than those carrying a short (4 atom) arm. The long linker arm derivs. are comparable to underivatized oligonucleotides in hybridizing to mRNA.  
 IT **114079-29-7P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and detoluoylation of)  
 RN 114079-29-7 CAPLUS  
 CN Carbamic acid, [3-[1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\beta$ -D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **114079-30-0P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and dimethoxytritylation of)  
 RN 114079-30-0 CAPLUS  
 CN Carbamic acid, [3-[1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 114079-31-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, with bis(diisopropylamino)methoxyphosphine)

RN 114079-31-1 CAPLUS

CN Carbamic acid, [3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 114079-33-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, with nitrophenyl aminohexanoate derivative)

RN 114079-33-3 CAPLUS


CN Uridine, 5-(3-amino-1-propynyl)-2'-deoxy-, 3',5'-bis(4-methylbenzoate), mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 114079-32-2

CMF C28 H27 N3 O7


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 114079-34-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation and sequential detoluoylation and dimethoxytritylation of)


RN 114079-34-4 CAPLUS

CN Carbamic acid, [6-[[3-[1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







IT 114079-35-5P 114079-36-6P 114103-42-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, intermediate in synthesis of fluorescent-labeled  
 oligodeoxyribonucleotides)  
 RN 114079-35-5 CAPLUS  
 CN Carbamic acid, [6-[[3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-  
 $\beta$ -D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-  
 pyrimidinyl]-2-propynyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 114079-36-6 CAPLUS  
 CN Carbamic acid, [6-[[3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-  
 [[bis(1-methylethyl)amino]methoxyphosphino]-2-deoxy- $\beta$ -D-erythro-  
 pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-  
 propynyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 114103-42-3 CAPLUS

CN Carbamic acid, [3-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-[[bis(1-methylethyl)amino]methoxyphosphino]-2-deoxy-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-2-propynyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L9 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1983:215932 CAPLUS  
 DN 98:215932  
 TI **Nucleic acid** related compounds. 39. Efficient conversion of 5-iodo to 5-alkynyl and derived 5-substituted uracil bases and nucleosides  
 AU Robins, Morris J.; Barr, Philip J.  
 CS Dep. Chem., Univ. Alberta, Edmonton, AB, T6G 2G2, Can.  
 SO Journal of Organic Chemistry (1983), 48(11), 1854-62  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA English  
 AB Coupling terminal alkynes with 5-iodo-1-methyluracil and 5-iodouracil nucleosides, protected as their p-toluoyl esters, gave high yields in the presence of (Ph<sub>3</sub>P)<sub>2</sub>PdCl<sub>2</sub> and CuI in warm Et<sub>3</sub>N. Several of the deprotected 5-alkynyl-2'-deoxyuridines, including 5-ethynyl-2'-deoxyuridine, had antiviral activity; their 5'-monophosphates inhibited thymidylate synthetase. Controlled hydrogenation of the 5-alkynyl side chain gave (Z)-5-alkenyl- or the saturated 5-alkyl-2'-deoxyuridines. This provides a stereocontrolled route to the known 5-ethyl- and 5-n-hexyl-2'-deoxyuridines as well as (E)-5-(2-bromovinyl)-2'-deoxyuridine. Hydration of the triple bond sometimes gave uracil-5-alkanones.  
 IT 77875-84-4P 77875-86-6P 77875-87-7P  
 77875-88-8P 77875-89-9P 77875-90-2P  
 77875-93-5P 77875-94-6P 77875-95-7P  
 77882-22-5P 85267-64-7P 85267-65-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and deprotection of)  
 RN 77875-84-4 CAPLUS  
 CN Uridine, 5-[4-[(4-methylbenzoyl)oxy]-1-butynyl]-, 2',3',5'-tris(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 77875-86-6 CAPLUS

CN Uridine, 5-(1-butynyl)-2'-deoxy-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-87-7 CAPLUS

CN Uridine, 2'-deoxy-5-(1-pentynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77875-88-8 CAPLUS

CN Uridine, 2'-deoxy-5-(1-hexynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 77875-89-9 CAPLUS

CN Uridine, 2'-deoxy-5-(1-heptynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-90-2 CAPLUS

CN Uridine, 2'-deoxy-5-(3,3-dimethyl-1-butynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-93-5 CAPLUS

CN Uridine, 2'-deoxy-5-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-propynyl]-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-94-6 CAPLUS

CN Uridine, 2'-deoxy-5-[4-[(tetrahydro-2H-pyran-2-yl)oxy]-1-butynyl]-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77875-95-7 CAPLUS


CN Uridine, 2'-deoxy-5-[5-[(4-methylbenzoyl)oxy]-1-pentynyl]-,  
3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 77882-22-5 CAPLUS

CN Uridine, 2'-deoxy-5-[4-[(4-methylbenzoyl)oxy]-1-butynyl]-,  
3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 85267-64-7 CAPLUS  
 CN Uridine, 2'-deoxy-5-(3-hydroxy-1-propynyl)-, 3',5'-bis(4-methylbenzoate)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85267-65-8 CAPLUS  
 CN Uridine, 2'-deoxy-5-(4-hydroxy-1-butynyl)-, 3',5'-bis(4-methylbenzoate)  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 77875-97-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and hydrogenation of)

RN 77875-97-9 CAPLUS

CN Uridine, 2'-deoxy-5-(1-hexynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 77875-96-8P 77875-98-0P 77875-99-1P

77876-00-7P 77876-01-8P 77887-18-4P

77887-19-5P 84559-05-7P 84582-78-5P


85267-61-4P 85267-67-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 77875-96-8 CAPLUS

CN Uridine, 5-(1-butynyl)-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-98-0 CAPLUS

CN Uridine, 2'-deoxy-5-(1-heptynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-99-1 CAPLUS

CN Uridine, 2'-deoxy-5-(3-hydroxy-1-propynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77876-00-7 CAPLUS

CN Uridine, 2'-deoxy-5-(4-hydroxy-1-butynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77876-01-8 CAPLUS

CN Uridine, 2'-deoxy-5-(5-hydroxy-1-pentynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77887-18-4 CAPLUS

CN Uridine, 2'-deoxy-5-(1-pentynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77887-19-5 CAPLUS

CN Uridine, 2'-deoxy-5-(3,3-dimethyl-1-butynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84559-05-7 CAPLUS

CN Uridine, 2'-deoxy-5-[4-[[4-methylphenyl]sulfonyl]oxy]-1-butynyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 84582-78-5 CAPLUS

CN Uridine, 5-(3-buten-1-ynyl)-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 85267-61-4 CAPLUS  
CN Uridine, 2'-deoxy-5-(4-hydroxy-1-butynyl)-, 3',5'-diacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 85267-67-0 CAPLUS  
CN Uridine, 5-(4-hydroxy-1-butynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1983:198636 CAPLUS  
DN 98:198636  
TI **Nucleic acid** related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides  
AU De Clercq, Erik; Descamps, Johan; Balzarini, Jan; Giziewicz, Jerzy; Barr, Philip J.; Robins, Morris J.  
CS Rega Inst. Med. Res., Kathol. Univ., Louvain, B-3000, Belg.  
SO Journal of Medicinal Chemistry (1983), 26(5), 661-6  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
AB Coupling of terminal alkynes with 5-iodo-1-(2,3,5-tri-O-p-toluoyl- $\beta$ -D-arabinofuranosyl)uracil and 5-iodo-3',5'-di-O-p-toluoyl-2'-deoxyuridine proceeded readily in Et<sub>3</sub>N with catalytic (Ph<sub>3</sub>P)<sub>2</sub>PdCl<sub>2</sub> and CuI. Deprotection gave 5-alkynyl-1- $\beta$ -D-arabinofuranosyluracil and 5-alkynyl-2'-deoxyuridine nucleosides. The 5-ethynyl, followed by 5-propynyl, products had the highest antiviral potency, with the 2'-deoxy derivs. being more effective than the arabinosyl compds. Activity was weak at hexynyl and disappeared at heptynyl. Inclusion of an  $\omega$ -hydroxy function diminished the antiviral effect. None of the 5-alkynyluracil nucleosides tested had sufficient selectivity to qualify as a candidate antiviral drug. Several of the compds. inhibited thymidylate synthetase, with 5-ethynyl-2'-deoxyuridine being the most cytotoxic against L1210 cells.  
IT 77875-96-8 77875-97-9 77875-98-0


77875-99-1 77876-00-7 77876-01-8  
77887-18-4 77887-19-5 84559-05-7  
84582-78-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(antiviral, antimetabolic, and antileukemia activity of)

RN 77875-96-8 CAPLUS

CN Uridine, 5-(1-butynyl)-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-97-9 CAPLUS

CN Uridine, 2'-deoxy-5-(1-hexynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-98-0 CAPLUS

CN Uridine, 2'-deoxy-5-(1-heptynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-99-1 CAPLUS

CN Uridine, 2'-deoxy-5-(3-hydroxy-1-propynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77876-00-7 CAPLUS

CN Uridine, 2'-deoxy-5-(4-hydroxy-1-butynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77876-01-8 CAPLUS

CN Uridine, 2'-deoxy-5-(5-hydroxy-1-pentynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77887-18-4 CAPLUS


CN Uridine, 2'-deoxy-5-(1-pentynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77887-19-5 CAPLUS  
CN Uridine, 2'-deoxy-5-(3,3-dimethyl-1-butynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 84559-05-7 CAPLUS  
CN Uridine, 2'-deoxy-5-[4-[[ (4-methylphenyl) sulfonyl]oxy]-1-butynyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 84582-78-5 CAPLUS  
CN Uridine, 5-(3-buten-1-ynyl)-2'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 84558-91-8P 84558-92-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and deprotection of)  
RN 84558-91-8 CAPLUS  
CN 2,4(1H,3H)-Pyrimidinedione, 5-(1-propynyl)-1-[2,3,5-tris-O-(4-  
methylbenzoyl)-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84558-92-9 CAPLUS

CN Uridine, 2'-deoxy-5-(1-propynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 77875-86-6P 84558-93-0P 84558-95-2P

84558-96-3P 84558-97-4P 84558-98-5P


84558-99-6P 84559-00-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 77875-86-6 CAPLUS

CN Uridine, 5-(1-butynyl)-2'-deoxy-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84558-93-0 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-β-D-arabinofuranosyl-5-(1-propynyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84558-95-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-(1-butynyl)-1-[2,3,5-tris-O-(4-methylbenzoyl)-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84558-96-3 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-β-D-arabinofuranosyl-5-(1-butynyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84558-97-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 5-(3,3-dimethyl-1-butynyl)-1-[2,3,5-tris-O-(4-methylbenzoyl)-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84558-98-5 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-β-D-arabinofuranosyl-5-(3,3-dimethyl-1-butynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84558-99-6 CAPLUS

CN Uridine, 2'-deoxy-5-(3-methoxy-1-propynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 84559-00-2 CAPLUS

CN Uridine, 2'-deoxy-5-(3-methoxy-1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 84558-94-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(prepn. and antiviral, antimetabolic, and antileukemia activity of)

RN 84558-94-1 CAPLUS

CN Uridine, 2'-deoxy-5-(1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1981:407669 CAPLUS


DN 95:7669

TI **Nucleic acid** related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with



# 5-iodouracil nucleosides

AU Robins, Morris J.; Barr, Philip J.  
 CS Dep. Chem., Univ. Alberta, Edmonton, AB, T6G 2G2, Can.  
 SO Tetrahedron Letters (1981), 22(5), 421-4  
 CODEN: TELEAY; ISSN: 0040-4039  
 DT Journal  
 LA English  
 GI



AB Reaction of terminal alkynes with protected uridines in the presence of Pd and Cu gave the corresponding 5-(alkyn-1-yl)uracil nucleosides in 72-92% yield. E.g., uridine I (R = iodo, R1 = p-MeC6H4) coupled with EtC.tplbond.CH in Et3N at 50° under N for 10 h in the presence of (Ph3P)PdCl2 and CuI to give 91% I (R = C.tplbond.CEt, R1 = p-MeC6H4) which was deprotected to give I (R = C.tplbond.CEt, R1 = H).


IT 77875-86-6P 77875-87-7P 77875-88-8P  
 77875-89-9P 77875-90-2P 77875-93-5P  
 77875-94-6P 77875-95-7P 77882-22-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and deprotection of)

RN 77875-86-6 CAPLUS


CN Uridine, 5-(1-butynyl)-2'-deoxy-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77875-87-7 CAPLUS  
CN Uridine, 2'-deoxy-5-(1-pentynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 77875-88-8 CAPLUS  
CN Uridine, 2'-deoxy-5-(1-hexynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 77875-89-9 CAPLUS  
CN Uridine, 2'-deoxy-5-(1-heptynyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 77875-90-2 CAPLUS

CN Uridine, 2'-deoxy-5-(3,3-dimethyl-1-butynyl)-, 3',5'-bis(4-methylbenzoate)  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-93-5 CAPLUS


CN Uridine, 2'-deoxy-5-[3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-propynyl]-,  
3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 77875-94-6 CAPLUS  
 CN Uridine, 2'-deoxy-5-[4-[(tetrahydro-2H-pyran-2-yl)oxy]-1-butynyl]-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 77875-95-7 CAPLUS  
 CN Uridine, 2'-deoxy-5-[5-[(4-methylbenzoyl)oxy]-1-pentynyl]-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 77882-22-5 CAPLUS


CN     Uridine, 2'-deoxy-5-[4-[(4-methylbenzoyl)oxy]-1-butynyl]-, 3',5'-bis(4-methylbenzoate) (9CI)     (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





IT 77875-84-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, by alkynylation of uridine)

RN 77875-84-4 CAPLUS

CN    Uridine, 5-[4-[(4-methylbenzoyl)oxy]-1-butynyl]-, 2',3',5'-tris(4-methylbenzoate) (9CI)    (CA INDEX NAME)

Absolute stereochemistry.




IT 77875-96-8P 77875-97-9P 77875-98-0P  
 77875-99-1P 77876-00-7P 77876-01-8P  
 77887-18-4P 77887-19-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, by alkynylation/deprotection of iodouridine)

RN 77875-96-8 CAPLUS

CN Uridine, 5-(1-butynyl)-2'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 77875-97-9 CAPLUS

CN Uridine, 2'-deoxy-5-(1-hexynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




n-Bu—C≡C

RN 77875-98-0 CAPLUS

CN Uridine, 2'-deoxy-5-(1-heptynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Me—  
(CH<sub>2</sub>)<sub>4</sub>—C≡C

RN 77875-99-1 CAPLUS

CN Uridine, 2'-deoxy-5-(3-hydroxy-1-propynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HO—C≡C

RN 77876-00-7 CAPLUS

CN Uridine, 2'-deoxy-5-(4-hydroxy-1-butynyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



HO—C≡C


RN 77876-01-8 CAPLUS  
CN Uridine, 2'-deoxy-5-(5-hydroxy-1-pentynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 77887-18-4 CAPLUS  
CN Uridine, 2'-deoxy-5-(1-pentynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 77887-19-5 CAPLUS  
CN Uridine, 2'-deoxy-5-(3,3-dimethyl-1-butynyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 09:00:10 ON 28 DEC 2004)

FILE 'REGISTRY' ENTERED AT 09:00:17 ON 28 DEC 2004

L1 STRUCTURE UPLOADED

L2 1171 S L1' FULL

FILE 'CAPLUS' ENTERED AT 09:00:43 ON 28 DEC 2004

L3 415 S L2



L4	123 S L3 AND NUCLEIC ACID
L5	123 DUP REM L4 (0 DUPLICATES REMOVED)
L6	123 S L5
L7	5 S L5 AND PY=1993
L8	123 S L5
L9	15 S L5 AND PY<=1993

=>

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

750.24

905.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-109.90

-109.90

FILE 'REGISTRY' ENTERED AT 09:35:34 ON 28 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

DICTIONARY FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

\*\*\* YOU HAVE NEW MAIL \*\*\*

=>


Uploading C:\Program Files\Stnexp\Queries\107306431.str

L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l10 full  
FULL SEARCH INITIATED 09:36:24 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1312 TO ITERATE

100.0% PROCESSED 1312 ITERATIONS 967 ANSWERS  
SEARCH TIME: 00.00.01

L11 967 SEA SSS FUL L10

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	155.84	1061.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-109.90

FILE 'CAPLUS' ENTERED AT 09:36:31 ON 28 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Dec 2004 VOL 142 ISS 1  
FILE LAST UPDATED: 24 Dec 2004 (20041224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11  
L12 703 L11

=> dup rem l12  
PROCESSING COMPLETED FOR L12  
L13 702 DUP REM L12 (1 DUPLICATE REMOVED)

=> s l13 and nucleic acid  
L14 702 S L13  
163616 NUCLEIC  
3916487 ACID  
117879 NUCLEIC ACID  
(NUCLEIC(W)ACID)  
L15 320 L14 AND NUCLEIC ACID

=> s l15 and py<=1993  
15254580 PY<=1993  
L16 107 L15 AND PY<=1993

FILE 'HOME' ENTERED AT 09:55:13 ON 28 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:55:21 ON 28 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

DICTIONARY FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

\*\*\* YOU HAVE NEW MAIL \*\*\*

=>


Uploading C:\Program Files\Stnexp\Queries\107306432.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full  
FULL SEARCH INITIATED 09:55:43 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1372 TO ITERATE

100.0% PROCESSED 1372 ITERATIONS 234 ANSWERS  
SEARCH TIME: 00.00.01

L2 234 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
155.42	155.63

FILE 'CAPLUS' ENTERED AT 09:55:54 ON 28 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Dec 2004 VOL 142 ISS 1  
FILE LAST UPDATED: 24 Dec 2004 (20041224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2  
L3 71 L2

=> dup rem l3  
PROCESSING COMPLETED FOR L3  
L4 70 DUP REM L3 (1 DUPLICATE REMOVED)

=> s l4 and nucleic acid  
L5 70 S L4  
163616 NUCLEIC  
3916487 ACID  
117879 NUCLEIC ACID  
(NUCLEIC(W)ACID)  
L6 12 L5 AND NUCLEIC ACID

=> d l6 bib abs hitstr 1-12


L6 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2003:584281 CAPLUS  
DN 139:257146  
TI Photochemical cross-linking of Escherichia coli Fpg protein to DNA duplexes containing phenyl(trifluoromethyl)diazirine groups  
AU Taranenko, Maria; Rykhlevskaya, Anna; Mtchedlidze, Manana; Laval, Jacques; Kuznetsova, Svetlana  
CS Laboratory of Nucleic Acids Chemistry, Department of Chemistry, Moscow

State University, Moscow, Russia  
 SO European Journal of Biochemistry (2003), 270(14), 2945-2949  
 CODEN: EJBCAI; ISSN: 0014-2956  
 PB Blackwell Publishing Ltd.  
 DT Journal  
 LA English  
 AB Formamidopyrimidine-DNA glycosylase (Fpg protein) of *Escherichia coli* is a DNA repair enzyme that excises oxidized purine bases, most notably the mutagenic 7-hydro-8-oxoguanine, from damaged DNA. In order to identify specific contacts between nucleobases of DNA and amino acids from the *E. coli* Fpg protein, photochem. crosslinking was employed using new reactive DNA duplexes containing 5-[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenyl]-2'-deoxyuridine dU\* residues near the 7-hydro-8-oxoguanosine (oxoG) lesion. The Fpg protein was found to bind specifically and tightly to the modified DNA duplexes and to incise them. The nicking efficiency of the DNA duplex containing a dU\* residue 5' to the oxoG was higher as compared to oxidized native DNA. The conditions for the photochem. crosslinking of the reactive DNA duplexes and the Fpg protein have been optimized to yield as high as 10% of the cross-linked product. Our results suggest that the Fpg protein forms contacts with two nucleosides, one 5' adjacent to oxoG and the other 5' adjacent to the cytidine residue pairing with oxoG in the other strand. The approaches developed may be applicable to pro- and eukaryotic homologs of the *E. coli* Fpg protein as well as to other repair enzymes.

IT 210107-39-4  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (Escherichia coli formamidopyrimidine-DNA glycosylase forms contacts with two nucleosides, one 5' adjacent to oxoG and other 5' adjacent to cytidine residue pairing with oxoG in other strand)

RN 210107-39-4 CAPLUS  
 CN Uridine, 2'-deoxy-5-[4-[3-(trifluoromethyl)-3H-diazirin-3-yl]phenyl]-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2003:534251 CAPLUS  
 DN 140:249471  
 TI Pyrene as a fluorescent probe for DNA base radicals  
 AU Huber, Robert; Fiebig, Torsten; Wagenknecht, Hans-Achim  
 CS Institute for Organic Chemistry and Biochemistry, Technical University of Munich, Garching, D-85747, Germany  
 SO Chemical Communications (Cambridge, United Kingdom) (2003), (15), 1878-1879  
 CODEN: CHCOFS; ISSN: 1359-7345  
 PB Royal Society of Chemistry  
 DT Journal


LA English  
 AB The steady-state emission spectra of 5-(1-pyrenyl)-modified pyrimidine and 8-(1-pyrenyl)-modified purine nucleosides in water at different pH values provide important information about the acidity or basicity of photochem. generated DNA base radicals which are key intermediates in DNA-mediated charge transport processes.  
 IT **167105-67-1 654668-75-4**  
 RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); BIOL (Biological study); PROC (Process)  
 (pyrene as a fluorescent probe for DNA base radicals)  
 RN 167105-67-1 CAPLUS  
 CN Uridine, 2'-deoxy-5-(1-pyrenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 654668-75-4 CAPLUS  
 CN Cytidine, 2'-deoxy-5-(1-pyrenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:876122 CAPLUS  
 DN 138:182628  
 TI Electron injection into DNA: Synthesis and spectroscopic properties of pyrenyl-modified oligonucleotides  
 AU Amann, Nicole; Pandurski, Evgeni; Fiebig, Torsten; Wagenknecht, Hans-Achim  
 CS Institute for Organic Chemistry and Biochemistry, Technical University of Munich, Garching, 85747, Germany  
 SO Chemistry--A European Journal (2002), 8(21), 4877-4883  
 CODEN: CEUJED; ISSN: 0947-6539  
 PB Wiley-VCH Verlag GmbH & Co. KGaA  
 DT Journal  
 LA English  
 OS CASREACT 138:182628  
 AB The nucleoside 5-(1-pyrenyl)-2'-deoxyuridine (1) was prepared by a Suzuki - Miyaura cross-coupling reaction and subsequently used as a DNA building block in order to prepare a range of modified oligonucleotides using

phosphoramidite chemical The DNA duplexes contain a pyrenyl group covalently attached to the nucleobase uracil. Upon excitation at 340 nm an intramol. electron transfer from the pyrenyl group to the uracil moiety takes place which represents an injection of an excess electron into the DNA base stack. Based on the results obtained by steady-state fluorescence and time-resolved pump-probe laser spectroscopy it was possible to show that base-to-base electron transfer can occur from the Py-dU group only to adjacent thymines.


IT **167105-67-1P**

RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)  
(base-to base electron transfer in DNA using 5-(1-pyrenyl)-2'-deoxyuridine as building block, transfer from pyrenyl-dU group to adjacent thymines)

RN 167105-67-1 CAPLUS

CN Uridine, 2'-deoxy-5-(1-pyrenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **499120-15-9P 499120-16-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(base-to base electron transfer in DNA using 5-(1-pyrenyl)-2'-deoxyuridine as building block, transfer from pyrenyl-dU group to adjacent thymines)

RN 499120-15-9 CAPLUS

CN Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-5-(1-pyrenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 499120-16-0 CAPLUS

CN Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-5-(1-pyrenyl)-, 3'-[2-cyanoethyl bis(1-methylethyl)phosphoramidite] (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1997:370662 CAPLUS  
DN 127:95255  
TI Preparation and reactions of new zincated nitrogen-containing heterocycles  
AU Prasad, A. S. Bhanu; Stevenson, Thomas M.; Citineni, Janakiram Rao; Nyzam, Valerie; Knochel, Paul  
CS Fachbereich Chemie der Philipps, Universitat Marburg, Marburg, 35032, Germany  
SO Tetrahedron (1997), 53(21), 7237-7254  
CODEN: TETRAB; ISSN: 0040-4020  
PB Elsevier  
DT Journal  
LA English  
OS CASREACT 127:95255  
AB A range of nitrogen-containing iodinated or in some cases brominated heterocycles were converted to the corresponding zincated heterocyclic derivs. by the direct insertion of zinc dust under mild conditions (25°C to 70 °C, 1-3 h) in a solvent like THF or DMAC. This reaction was extended to the preparation of zincated **nucleic acid** bases and nucleosides. The reaction of these new zinc reagents toward various electrophiles with palladium (0) or copper(I) catalysis allows the preparation of a broad range of polyfunctional nitrogen-containing heterocycles.  
IT **185386-81-6P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and catalytic electrophilic addition reactions of zincated nitrogen heterocycles)  
RN 185386-81-6 CAPLUS  
CN Uridine, 3-methyl-5-[3-(trifluoromethyl)phenyl]-, 2',3',5'-triacetate (9CI). (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:143042 CAPLUS

DN 126:260905

TI Mechanistic studies relevant to bromouridine-enhanced nucleoprotein photocrosslinking: possible involvement of an excited tyrosine residue of the protein

AU Norris, Christopher L.; Meisenheimer, Kristen M.; Koch, Tad H.

CS Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO, 80309-0215, USA

SO Photochemistry and Photobiology (1997), 65(2), 201-207

CODEN: PHCBAP; ISSN: 0031-8655

PB American Society for Photobiology

DT Journal

LA English

AB The results of mechanistic studies on formation of uridine (U) and N-acetyl-m-(5-uridinyl)tyrosine N-ethylamide (I) from irradiation of aqueous, pH 7

solns. of bromouridine (BrU) and N-acetyltyrosine N-ethylamide (II) are reported. Solns. were irradiated with monochromatic laser emission at 266, 308, and 325 nm. Quantum yield measurements as a function of excitation wavelength suggest that both products result from excitation of the tyrosine derivative followed by electron transfer to BrU, possibly with intermediacy of the hydrated electron. The BrU radical anion ejects bromide to form the uridinyl radical, which then abstrs. a hydrogen atom from II or adds to the aromatic ring of II. Formation of adduct I is a model for photocrosslinking of nucleic acids bearing the bromouracil chromophore to adjacent tyrosine residues of proteins in nucleoprotein complexes. The value of 325 nm excitation in photocrosslinking, where the tyrosine chromophore is more competitive for photons, was demonstrated with an RNA bound to the MS2 bacteriophage coat protein; >60% increase in the yield of photocrosslinking relative to that obtained with 308 nm excitation was achieved.

IT 177601-16-0P


RL: SPN (Synthetic preparation); PREP (Preparation)

(bromouridine-enhanced nucleoprotein photocrosslinking with possible involvement of excited tyrosine of protein)

RN 177601-16-0 CAPLUS


CN Benzenepropanamide,  $\alpha$ -(acetylamino)-N-ethyl-4-hydroxy-3-(1,2,3,4-tetrahydro-2,4-dioxo-1- $\beta$ -D-ribofuranosyl-5-pyrimidinyl)-, (S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:711245 CAPLUS  
 DN 126:75169  
 TI Preparation of zinc organometallics derived from nucleosides and  
 nucleic acid bases and Pd(0) catalyzed coupling with  
 aryl iodides  
 AU Stevenson, Thomas M.; Prasad, A. S. Bhanu; Citineni, Janakiram Rao;  
 Knochel, Paul  
 CS Fachbereich Chemie, Philipps-Univ. Marburg, Marburg, D-35032, Germany  
 SO Tetrahedron Letters (1996), 37(46), 8375-8378  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier  
 DT Journal  
 LA English  
 OS CASREACT 126:75169  
 AB 5-Iodouracils and 6-iodopurines readily insert zinc dust (25 °C or  
 70 °C) in THF or N,N-dimethylacetamide (DMAC) affording zincated  
 nucleobases which undergo efficient palladium catalyzed cross-coupling  
 reactions with aryl iodides in good yields. This reaction sequence has  
 been extended to two nucleosides.  
 IT 185386-81-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of zinc organometallics derived from nucleosides and  
 nucleic acid bases and pd catalyzed coupling with  
 aryl iodides)  
 RN 185386-81-6 CAPLUS  
 CN Uridine, 3-methyl-5-[3-(trifluoromethyl)phenyl]-, 2',3',5'-triacetate  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1996:323734 CAPLUS  
 DN 125:29148  
 TI Mechanistic Studies of the 5-Iodouracil Chromophore Relevant to Its Use in

# Nucleoprotein Photo-Crosslinking

AU Norris, Christopher L.; Meisenheimer, Poncho L.; Koch, Tad H.  
 CS Department of Chemistry and Biochemistry, University of Colorado, Boulder,  
 CO, 80309-0215, USA

SO Journal of the American Chemical Society (1996), 118(24), 5796-5803  
 CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

AB The photoreactivity of the 5-iodouracil chromophore was investigated toward understanding photocrosslinking of nucleic acids bearing the chromophore to functionality in associated proteins. Irradiation of 5-iodouridine (IU) in the presence of a 10-fold excess of N-acetyltyrosine N-ethylamide (1) at 308 nm with a XeCl excimer laser or at 325 nm with a HeCd laser yields uridine (U) and N-acetyl-m-(5-uridinyl)tyrosine N-ethylamide (2) in a 1:2 mol ratio. In the presence of N-acetylphenylalanine N-ethylamide, uridine and analogous ortho, meta, and para regioisomeric adducts (3o, 3m, and 3p) were formed in a similar U to adduct mole ratio. The primary photochem. process leading to products was established as carbon-iodine bond homolysis in the first excited singlet state from a deuterium labeling experiment, photoacoustic calorimetry, and quantum yield measurements. Photoredn. of IU in 2-propanol-d solvent gave U with no deuterium incorporation. Photoacoustic calorimetric measurements established that triplet benzophenone transferred energy to IU with a rate constant of  $2 + 109 \text{ M}^{-1} \text{ s}^{-1}$ . Further, the reaction of IU with 1 to form 2 was sensitized by benzophenone; however, comparison of quantum yields upon direct and sensitized excitation indicated that, at most, only a small portion of the reactions occurred via the triplet state. With direct excitation of IU, quantum yields as a function of the concentration of 1 showed that U and adduct 2 resulted from a common

intermediate

proposed to be the 5-uridinyl radical. Uridine formation was enhanced by the presence of hydrogen atom donors at the expense of formation of 2. Quantum yields were independent of excitation wavelength in the region 310-330 nm but not the reaction medium. The quantum yield of uridine formation but not adduct formation was approx. an order of magnitude higher in 90% acetonitrile-10% water than in pH 7 water. The results are discussed in terms of high-yield crosslinking of nucleic acids bearing the 5-iodouracil chromophore to associated proteins in light of cocrystal x-ray structural data.


IT 177601-16-0 177601-17-1 177601-18-2  
 177601-19-3

RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)  
 (mechanistic studies of 5-iodouracil chromophore relevant to its use in nucleoprotein photocrosslinking)

RN 177601-16-0 CAPLUS


CN Benzenepropanamide,  $\alpha$ -(acetylamino)-N-ethyl-4-hydroxy-3-(1,2,3,4-tetrahydro-2,4-dioxo-1- $\beta$ -D-ribofuranosyl-5-pyrimidinyl)-, (S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 177601-17-1 CAPLUS  
CN Benzenepropanamide,  $\alpha$ -(acetylamino)-N-ethyl-3-(1,2,3,4-tetrahydro-2,4-dioxo-1- $\beta$ -D-ribofuranosyl-5-pyrimidinyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 177601-18-2 CAPLUS  
CN Benzenepropanamide,  $\alpha$ -(acetylamino)-N-ethyl-2-(1,2,3,4-tetrahydro-2,4-dioxo-1- $\beta$ -D-ribofuranosyl-5-pyrimidinyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177601-19-3 CAPLUS  
CN Benzenepropanamide,  $\alpha$ -(acetylamino)-N-ethyl-4-(1,2,3,4-tetrahydro-2,4-dioxo-1- $\beta$ -D-ribofuranosyl-5-pyrimidinyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1995:931223 CAPLUS  
DN 124:30268  
TI Preparation of binding competent oligomers containing unsaturated 3',5'

and 2',5' linkages and related compounds.

IN Matteucci, Mark D.; Cao, Xiaodong

PA Gilead Sciences, Inc., USA

SO PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511911	A1	19950504	WO 1994-US12202	19941025
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5434257	A	19950718	US 1993-142785	19931026
PRAI	US 1993-142785	A	19931026		
	US 1992-892902	A2	19920601		

AB Oligomers having  $\geq 1$  substitute linkage of the form 2'/3' -O-CH<sub>2</sub>-CH: 5' or 3' -S-CH<sub>2</sub>-CH: 5' between adjacent nucleomonomers, and related compds., are disclosed. The oligonucleotide analogs are easy to synthesize, stable in vivo, resistant to endogenous nucleases and are able to hybridize to target **nucleic acid** sequences in a sequence specific manner. Thus, 5' TCTCTCTCTCT#TT#TT 3' (# = 3' allyl sulfide linkage; C = 5-methylcytidine) showed a  $\Delta T_m$ /sub. = -1.50° for binding to a single stranded RNA target.

IT **169243-63-4P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of binding competent oligomers containing unsatd. 3',5' and 2',5' linkages and related compds.)

RN 169243-63-4 CAPLUS

CN Carbamic acid, [2-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy- $\beta$ -D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:871986 CAPLUS

DN 123:314400

TI Preparation of fused pyrimidine derivatives as fluorescence-labeled binding partners for oligodeoxyribonucleotides

IN Matteucci, Mark D.; Jones, Robert J.; Lin, Kuei-Ying

PA Gilead Sciences, Inc., USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9507918	A2	19950323	WO 1994-US10536	19940916
	WO 9507918	A3	19950803		
	W: JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5502177	A	19960326	US 1993-123505	19930917
	EP 719272	A1	19960703	EP 1994-929830	19940916
	EP 719272	B1	20030507		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 09506859	T2	19970708	JP 1994-509393	19940916
	AT 239752	E	20030515	AT 1994-929830	19940916
	US 6005096	A	19991221	US 1995-436991	19950508
	US 5763588	A	19980609	US 1995-481719	19950607
	US 6617437	B1	20030909	US 1999-468454	19991221
	US 2003207824	A1	20031106	US 2002-294066	20021114
PRAI	US 1993-123505	A	19930917		
	WO 1994-US10536	W	19940916		
	US 1995-436991	A1	19950508		
	US 1999-468454	A1	19991221		


OS MARPAT 123:314400

GI For diagram(s), see printed CA Issue.

AB Fused pyrimidine compds. [I; R1 = a binding partner, a linker, H; a, b = 0 or 1 and a + b = 0 or 1; A = N or C; X = S, O, CO, NH, NCH2R6; Y = CO; Z is taken together with A to form an aryl or heteroaryl ring structure comprising 5 or 6 ring atoms wherein the heteroaryl ring comprises a single O ring heteroatom, a single N ring heteroatom, a single S ring heteroatom, a single O and a single N ring heteroatom separated by a carbon atom, a single S and a single N ring heteroatom separated by a carbon atom 2 N ring heteroatoms separated by a carbon atom, or 2 N ring heteroatoms at least two of which are separated by a carbon atom, and wherein the aryl or heteroaryl ring carbon atoms are unsubstituted with other than H or at least 1 nonbridging ring carbon atom is substituted with R6 or oxo; R6 = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, NO2, (un)protected NH2, cyano, halo; an R6 is taken together with an adjacent R6 to complete a ring containing 5 or 6 ring atoms; provided that when a = 0 and b = 1, and R1 = Q; wherein D2 = (un)protected OH, mono-, di- or triphosphate, or an oligodeoxyribonucleotide otherwise containing only the bases A, G, T and C; D3 = H or OH; then Z ≠ unsubstituted Ph], useful as therapeutics and labels in diagnostics, are prepared These compds. increase the hybridization affinity of oligonucleotides for their complementary sequences, provide improved detectable labels for use in diagnostic assays, enhance diagnostic assays which employ oligonucleotides, and also improve the therapeutic efficacy of oligonucleotides. Thus, 5-iodo-2'-deoxyuridine was condensed with N-tert-butoxycarbonyl-2-(trimethylstannyl)aniline in the presence of (Ph3P)2PdCl2 in DMF at 50°, followed by tritylation with dimethoxytrityl chloride in pyridine at 20° for 1 h, to give 5-(2-N-tert-butoxycarbonylanilino)-5'-dimethoxytrityl-2'-deoxyuridine, which was cyclized by treatment with (1) Me3SiNMe2 in MeCN at 20° for 2 h, (2) mesitylenesulfonyl chloride and 4-dimethylaminopyridine in MeCN at 20° for 4 h, (3) DBU for 30 min at 20°, and (4) H2O for 1 h to give a benzopyrimidine tricyclic nucleoside (II; X = bond, R = H, DMT = 4,4'-dimethoxytrityl). Other tricyclic pyrimidine nucleosides II (X = O, S; R = H) and a tetracyclic pyrimidine nucleoside (III) were also prepared, converted into its 3' hydrogen phosphonate derivative, e.g. II [R = PH(O)O-.Et3N+H], and incorporated into oligonucleotides by standard procedures (no details given). The oligonucleotides containing fused pyrimidine nucleosides I showed enhanced RNA affinity.


IT 169243-63-4P 169243-64-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of fused pyrimidine nucleoside derivs. as  
 intermediates for fluorescence-labeled oligodeoxyribonucleotides in  
 diagnostics and therapeutics)  
 RN 169243-63-4 CAPLUS  
 CN Carbamic acid, [2-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-  
 $\beta$ -D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-  
 pyrimidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169243-64-5 CAPLUS  
 CN Carbamic acid, [2-[1-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-1,2,3,4-  
 tetrahydro-2,4-dioxo-5-pyrimidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1995:759132 CAPLUS  
 DN 124:146760  
 TI Oligonucleotide analogs containing unsaturated 3',5' and 2',5' allyl ether  
 and allyl sulfide linkages capable of hybridizing to target  
 nucleic acid sequences  
 IN Matteucci, Mark D.; Cao, Xiaodong  
 PA Gilead Sciences, Inc., USA  
 SO U.S., 77 pp. Cont.-in-part of U.S. Ser. No. 892,902.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3  
 PATENT NO. KIND DATE APPLICATION NO. DATE



PI	US 5434257	A	19950718	US 1993-142785	19931026
	US 5817781	A	19981006	US 1992-892902	19920601
	AT 174599	E	19990115	AT 1993-915177	19930601
	WO 9511911	A1	19950504	WO 1994-US12202	19941025
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6410702	B1	20020625	US 1998-165883	19981002
	US 2003120050	A1	20030626	US 2002-176763	20020621
	US 6683166	B2	20040127		
PRAI	US 1992-892902	A2	19920601		
	US 1993-142785	A	19931026		
	US 1998-165883	A1	19981002		
OS	MARPAT 124:146760				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Oligonucleotide analogs I and II where X is S, O, CH<sub>2</sub>, CHF or CF<sub>2</sub> ; X<sub>1</sub> is O or S; R<sub>1</sub> is independently H, an oligomer or a blocking group including PO<sub>3</sub>-2, O-dimethoxytrityl (DMTO), O-monomethoxytrityl (MMTO), H-phosphonate (OPO<sub>2</sub>H), methylphosphonate (OPO<sub>3</sub>CH<sub>3</sub>), methylphosphonamidite, or a phosphoramidite such as β-cyanoethylphosphoramidite; R<sub>2</sub> independently is O-alkyl (C<sub>1</sub>-C<sub>12</sub> including O-Me, O-Et, O-Pr, O-Bu and their isomers), S-alkyl (C<sub>1</sub>-C<sub>12</sub>), H, OH, OCH<sub>3</sub>, SCH<sub>3</sub>, OCH<sub>2</sub>CH:CH<sub>2</sub> (O-allyl), OC<sub>3</sub>H<sub>7</sub> (O-propyl), SCH<sub>2</sub>CHCH<sub>2</sub>, or a halogen (F, Cl, Br or I); B is independently a base, and n is 0-100, preferably 0-28; both R<sub>1</sub> taken together can comprise a circular oligomer and may be covalently linked, for example, at a terminal 5' position with a terminal 2' or 3' position, are disclosed. The substitute linkage replace the usual phosphodiester linkage found in unmodified nucleic acids. The oligonucleotide analogs are easy to synthesize, stable in vivo, resistant to endogenous nucleases and are able to hybridize to target **nucleic acid** sequences in a sequence specific manner. Thus, e.g., 3'-H-phosphonate dimers III (X = O, S, preparation given) were incorporated into oligomers (5' TCT CTC TCT CT#T T#TT 3'; # = X-containing linkage) and tested for binding to single stranded DNA (3' AGA GAG AGA GAA AAA 5'): ΔT<sub>m</sub> was -3.25 and -3.0°, resp., for X = O and X = S.

IT **169243-63-4P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(oligonucleotide analogs containing unsatd. 3',5' and 2',5' allyl ether and allyl sulfide linkages capable of hybridizing to target **nucleic acid** sequences)


RN 169243-63-4 CAPLUS

CN Carbamic acid, [2-[1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-β-D-erythro-pentofuranosyl]-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1992:647824 CAPLUS  
 DN 117:247824  
 TI Enhancement of thermal neutron induced killing effect on HeLa cells containing boron-10 **nucleic acid** derivatives  
 AU Ujeno, Y.; Akaboshi, M.; Akuta, K.; Maki, T.; Kawai, K.; Yamamoto, Y.  
 CS Res. React. Inst., Kyoto Univ., Osaka, 590-04, Japan  
 SO Prog. Neutron Capture Ther. Cancer, [Proc. Int. Symp.], 4th (1992), Meeting Date 1990, 349-51. Editor(s): Allen, Barry J.; Moore, Douglas E.; Harrington, Baiba V. Publisher: Plenum, New York, N. Y.  
 CODEN: 58COA3  
 DT Conference  
 LA English  
 AB The present study deals with the enhanced killing of HeLa S3 cells containing boron-10 nucleic acids in vitro by irradiation in the thermal neutron beam of the Kyoto University Reactor (KUR). The enhancement was measured by the changes in 4 radiobiol. parameters.  
 IT **144601-99-0**  
 RL: BIOL (Biological study)  
 (neutron lethality to HeLa cells enhancement by)  
 RN 144601-99-0 CAPLUS  
 CN Uridine, 5-[4-(boryl-10B)phenyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1981:192661 CAPLUS  
 DN 94:192661  
 TI Organic chemical approach to photo-cross-links of nucleic acids to proteins  
 AU Matsuura, Teruo; Saito, Isao; Ito, Satoru; Sugiyama, Hiroshi; Shinmura, Tetsuya  
 CS Dep. Synth. Chem., Kyoto Univ., Kyoto, 606, Japan  
 SO Pure and Applied Chemistry (1980), 52(12), 2705-15  
 CODEN: PACHAS; ISSN: 0033-4545  
 DT Journal  
 LA English

AB Model systems for the photochem. crosslinkage of nucleic acids to proteins were studied. 5-Bromouracil and its derivs. underwent selective photocoupling to tryptophan, indoles, and electron-rich aromatic compds. under various irradiation conditions. Four types of reaction mechanism were observed: triplet coupling of bromouracils, a double electron transfer in the presence of an electron carrier, mixed aggregate formation in aqueous frozen solution, and fluorescence quenching of the aroms. by bromouracil. The stereochem. of photocoupling was studied by examination of the spectral and photochem. behavior of 8 of tryptophan-pyrimidine base derivs., and the photoreactions of other bases to amino acids is reported.


IT **75759-65-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and hydrolysis of)

RN 75759-65-8 CAPLUS

CN Uridine, 2',3'-O-(1-methylethylidene)-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **75759-66-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 75759-66-9 CAPLUS

CN Uridine, 5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:04:16 ON 28 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:04:26 ON 28 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

DICTIONARY FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

\*\*\* YOU HAVE NEW MAIL \*\*\*

=>


Uploading C:\Program Files\Stnexp\Queries\107306433.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full  
FULL SEARCH INITIATED 10:04:48 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 78 TO ITERATE

100.0% PROCESSED 78 ITERATIONS 7 ANSWERS  
SEARCH TIME: 00.00.01

L2 7 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 155.42 155.63

FILE 'CAPLUS' ENTERED AT 10:04:52 ON 28 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Dec 2004 VOL 142 ISS 1  
FILE LAST UPDATED: 24 Dec 2004 (20041224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

\*\*\* YOU HAVE NEW MAIL \*\*\*


=> s l2  
L3 6 L2

=> d l3 bib abs hitstr 1-6


L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1997:456106 CAPLUS  
DN 127:190987  
TI Enhanced triple-helix and double-helix formation with  
oligodeoxyribonucleotides containing modified pyrimidines  
IN Froehler, Brian; Wagner, Rick; Matteucci, Mark; Jones, Robert J.;  
Gutierrez, Arnold J.; Pudlo, Jeff  
PA Gilead Sciences, Inc., USA  
SO U.S., 104 pp., Cont.-in-part of U.S. Ser. No. 965,941, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5645985	A	19970708	US 1992-976103	19921125
	US 5484908	A	19960116	US 1991-799824	19911126

EP 1256589	A2	20021113	EP 2002-13297	19921124
EP 1256589	A3	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
TW 393513	B	20000611	TW 1993-82101747	19930308
AU 9463453	A1	19940915	AU 1994-63453	19940601
AU 679508	B2	19970703		
US 6235887	B1	20010522	US 1994-338352	19941114
US 5830653	A	19981103	US 1995-473481	19950607
US 6380368	B1	20020430	US 1996-599738	19960212
US 2003096980	A1	20030522	US 2001-24818	20011218
US 2003170680	A1	20030911	US 2002-294203	20021114
US 2004220395	A1	20041104	US 2003-730643	20031208
PRAI US 1991-799824	A2	19911126		
US 1992-935444	B2	19920825		
US 1992-965941	B2	19921023		
EP 1993-900636	A3	19921124		
US 1992-976103	A	19921125		
US 1994-338352	A1	19941114		
US 1996-599738	A3	19960212		
US 2001-24818	A1	20011218		
US 2002-294203	A3	20021114		
OS	MARPAT 127:190987			
GI				



I



II

AB Nucleomonomer nucleosides I and II [X = O, S; R1 = H, blocking group; H-phosphonate, phosphoramidite, alkylphosphonamidite; R2 = (un)substituted alkenyl or alkynyl, alkynylheteroaryl; Pr = (H)2 or protecting group; R3 = H, OH, F, OMe, OEt, SMe, SEt] were prepared and incorporated into DNA duplexes and triplexes. Novel oligodeoxyribonucleotides are disclosed which have enhanced ability with respect to forming duplexes or triplexes compared with oligomers containing only conventional bases. The oligomers contain the bases 5-(1-propynyl)uracil, 5-(1-propynyl)cytosine or related analogs. The oligomers of the invention are capable of (i) forming triplexes with various target sequences such as virus or oncogene sequences by coupling into the major groove of a target DNA duplex at physiol. pH or (ii) forming duplexes by binding to single-stranded DNA or to RNA encoded by target genes. The oligomers of the invention can be constructed to have any desired sequence, provided the sequence normally includes one or more bases that is replaced with the analogs of the invention. Compns. of the invention can be used for diagnostic purposes in order to detect viruses or disease conditions. Thus, 5-propynyl-2'-O-allyluridine was prepared and incorporated into DNA duplexes

and triplexes.

IT 143325-17-1P 151091-78-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(enhanced triple-helix and double-helix formation with oligodeoxyribonucleotides containing modified pyrimidines)

RN 143325-17-1 CAPLUS

CN Cytidine, 2'-deoxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151091-78-0 CAPLUS

CN Uridine, 2'-deoxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:631025 CAPLUS

DN 123:74138

TI Substrate specificities of mitochondrial thymidine kinase and cytosolic deoxycytidine kinase against 5-aryl substituted pyrimidine-2'-deoxyribose analogs

AU Eriksson, Staffan; Wang, Jianghai; Gronowitz, Salo; Johansson, Nils Gunnar  
CS Department Veterinary Medical Chemistry, Swedish University Agricultural Sciences, Uppsala, S-75123, Swed.

SO Nucleosides & Nucleotides (1995), 14(3-5), 507-10  
CODEN: NUNUD5; ISSN: 0732-8311

PB Dekker

DT Journal

LA English

AB Some 5-aryl-2'-deoxyuridine and -deoxycytidine analogs, many with known antiviral activity, were evaluated as substrates for pure deoxycytidine kinase (dCK) and pure mitochondrial thymidine kinase (TK2). Some of the deoxyuridine compds. were also tested with pure cytosolic thymidine kinase (TK1). TK2 showed the highest phosphorylation activity with this type of analogs.

IT 143325-17-1

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)


(substrate specificities of cytosolic and mitochondrial thymidine

kinase and cytosolic deoxycytidine kinase against 5-aryl substituted pyrimidine-2'-deoxyribose analogs)

RN 143325-17-1 CAPLUS

CN Cytidine, 2'-deoxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:436104 CAPLUS

DN 121:36104

TI 5-Heteroaryl-2'-deoxyuridine Analogs. Synthesis and Incorporation into High-Affinity Oligonucleotides

AU Gutierrez, Arnold J.; Terhorst, Terry J.; Matteucci, Mark D.; Froehler, Brian C.

CS Gilead Sciences Inc., Foster City, CA, 94404, USA


SO Journal of the American Chemical Society (1994), 116(13), 5540-4  
CODEN: JACSAT; ISSN: 0002-7863

DT Journal

LA English

OS CASREACT 121:36104

GI



AB C-5 heteroaryl-2'-deoxyuridines I (R = R1, R2; X = S, X1 = CH, N; X = NH, X1 = N), were synthesized from 5-iodo-2'-deoxyuridine. Palladium-catalyzed coupling with heteroarylstannanes proved to be a convenient and general method of preparation Oligonucleotides containing I gave

enhanced thermal stability to complementary RNA relative to thymidine. Thermal denaturation studies showed that oligodeoxynucleotides (ODNs) containing 5-(thiazol-2-yl)-2'-deoxyuridine exhibit the highest thermal denaturation (Tm) and therefore may increase the potency of these ODNs to inhibit gene expression in a sequence-specific manner.

IT 151091-78-0P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and incorporation of, into oligodeoxyribonucleotide duplex RNA)



RN 151091-78-0 CAPLUS  
CN Uridine, 2'-deoxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1993:642931 CAPLUS  
DN 119:242931  
TI Enhanced triple- and double-helix formation with oligomers containing modified pyrimidines  
IN Froehler, Brian; Wagner, Rick; Matteucci, Mark; Jones, Robert J.; Gutierrez, Arnold J.; Pudlo, Jeff  
PA Gilead Sciences, Inc., USA  
SO PCT Int. Appl., 170 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310820	A1	19930610	WO 1992-US10115	19921124
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, PT, RO, RU, SD, SE				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	US 5484908	A	19960116	US 1991-799824	19911126
	AU 9332227	A1	19930628	AU 1993-32227	19921124
	EP 637965	A1	19950215	EP 1993-900636	19921124
	EP 637965	B1	20021016		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07501527	T2	19950216	JP 1992-509622	19921124
	EP 1256589	A2	20021113	EP 2002-13297	19921124
	EP 1256589	A3	20030917		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 226093	E	20021115	AT 1993-900636	19921124
	AU 9463453	A1	19940915	AU 1994-63453	19940601
	AU 679508	B2	19970703		
	US 6235887	B1	20010522	US 1994-338352	19941114
	US 2003096980	A1	20030522	US 2001-24818	20011218
	US 2003170680	A1	20030911	US 2002-294203	20021114
PRAI	US 1991-799824	A	19911126		
	US 1992-935444	A	19920825		
	US 1992-965941	A	19921023		
	EP 1993-900636	A3	19921124		
	WO 1992-US10115	A	19921124		
	US 1996-599738	A3	19960212		
	US 2001-24818	A1	20011218		

AB The modified pyrimidines such as 5-(1-propynyl)uracil or 5-(1-propynyl)cytosine are prepared by substitution at the 5-position. Hybridized with double- and single-stranded nucleic acids, resp., the

oligonucleotides containing the modified pyrimidines have enhanced formation of triple- and double-helix structures. The oligonucleotides are useful as pharmaceuticals for treatment of virus-associated diseases, for detection of double- or single-stranded nucleic acids, for amplification of nucleic acids, and for inhibition of target gene expression. Preparation of 5-(1-propynyl)-2'-deoxyuridine H-phosphonate and oligonucleotides containing the 5-propynyl uracil, and the enhanced formation of triple- and double-helix structures with the oligonucleotides were shown.

IT 143325-17-1 151091-78-0


RL: USES (Uses)

(oligonucleotides containing, for enhanced formation of triple- and double-helix for treatment of virus-associated diseases)

RN 143325-17-1 CAPLUS

CN Cytidine, 2'-deoxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151091-78-0 CAPLUS

CN Uridine, 2'-deoxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:531487 CAPLUS

DN 117:131487

TI Synthesis and antiviral activity of various 5-substituted 2'-deoxyuridines and -cytidines

AU Peters, Dan; Hoernfeldt, Anna Britta; Gronowitz, Salo; Johansson, Nils Gunnar

CS Chem. Cent., Lund, S-221 00, Swed.

SO Nucleosides & Nucleotides (1992), 11(6), 1151-73

CODEN: NUNUD5; ISSN: 0732-8311

DT Journal

LA English

AB 5-Cyclopropyl-2'-deoxycytidine and some 5-aryl-2'-deoxyuridines and -cytidines have been prepared and their inhibition of HIV have been tested.

IT 143324-91-8P 143324-92-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and deblocking of)

RN 143324-91-8 CAPLUS

CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143324-92-9 CAPLUS

CN Cytidine, 2'-deoxy-5-(2-pyridinyl)-, 3',5'-bis(4-methylbenzoate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 143325-16-0P 143325-17-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 143325-16-0 CAPLUS


CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy- $\alpha$ -D-erythro-pentofuranosyl)-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143325-17-1 CAPLUS  
 CN Cytidine, 2'-deoxy-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1990:235778 CAPLUS  
 DN 112:235778  
 TI Preparation of pyrimidine nucleosides as virucides and their intermediates  
 IN Johansson, K. Nils Gunnar; Malmberg, Hans C. G.; Noreen, Rolf; Sahlberg, S. Christer; Sohn, Daniel D.; Gronowitz, Salo  
 PA Medivir AB, Swed.  
 SO PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8912061	A1	19891214	WO 1989-SE322	19890607
	W: AU, DK, FI, HU, JP, KR, NO, US				
	CA 1339313	A1	19970819	CA 1989-601897	19890606
	AU 8937504	A1	19900105	AU 1989-37504	19890607
	AU 637574	B2	19930603		
	EP 357571	A2	19900307	EP 1989-850184	19890607
	EP 357571	A3	19900613		
	EP 357571	B1	19960403		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03504969	T2	19911031	JP 1989-506227	19890607
	JP 2851094	B2	19990127		
	HU 57230	A2	19911128	HU 1989-4340	19890607
	HU 211736	B	19951228		
	EP 691333	A2	19960110	EP 1995-113626	19890607
	EP 691333	A3	19960214		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 136308	E	19960415	AT 1989-850184	19890607
	ES 2087090	T3	19960716	ES 1989-850184	19890607
	NO 9005300	A	19910206	NO 1990-5300	19901207
	NO 175981	B	19941003		
	NO 175981	C	19950111		
	DK 9002918	A	19910207	DK 1990-2918	19901207
	FI 94643	B	19950630	FI 1990-6053	19901207
	FI 94643	C	19951010		
	US 5440040	A	19950808	US 1991-613900	19910118
	US 5576429	A	19961119	US 1995-395877	19950228
PRAI	SE 1988-2173	A	19880610		
	EP 1989-850184	A3	19890607		
	WO 1989-SE322	A	19890607		
	US 1991-613900	A3	19910118		
OS	MARPAT 112:235778				
GI					



AB The title compds. [I; R1 = OH, NH<sub>2</sub>; R2 = (hetero)aryl, e.g. Q-Q2; X = O, S, Se, (un)substituted NH; R3 = H, OH, F, OMe; R4 = H, F, OH or its ether or ester residue, OMe, cyano, C.tplbond.CH, N<sub>3</sub>; R5 = OH or its ether or ester residue, (CH<sub>2</sub>)<sub>n</sub>P(O)(OM)<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>P(O)(OM)CH<sub>2</sub>P(O)(OM)<sub>2</sub>; R6 = H, straight or branched C1-10 alkyl, halo, etc.; M = H, a pharmaceutically acceptable counterion; n = 0, 1], useful for treatment of infections by viruses requiring reverse transcriptase for replication, e.g. human immunodeficiency virus (HIV) and hepatitis B virus, were prepared. Thus, silylation of 5-(2-thienyl)uracil (II) with hexamethyldisilazane in the presence of Me<sub>3</sub>SiCl and (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> under reflux gave bis-trimethylsilylated II which was stirred overnight with 2-deoxy-3,5-di-O-p-toluoyl-D-ribofuranosyl chloride in ClCH<sub>2</sub>CH<sub>2</sub>Cl in the presence of mol. sieve 4A. The product was treated with MeONa in MeOH to give α- and β-I (R1 = R4 = R5 = OH, R2 = 2-thienyl, R3 = H). α-I in vitro showed IC<sub>50</sub> of 0.05-10 μM against HIV in H9 cells. Analogously prepared and tested were addnl. 26 I. Cellular toxicity of I on H9 and F500 cells and inhibition of enzymes (e.g. HIV reverse transcriptase, hepatitis B virus DNA polymerase, and herpes simplex virus type 2 DNA polymerase) by I were also given.

IT **127235-49-8P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of pyrimidine nucleoside virucide)

RN 127235-49-8 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-α-D-erythro-pentofuranosyl]-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **127235-69-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of, as virucide)

RN 127235-69-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy- $\alpha$ -D-erythro-pentofuranosyl)-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:07:26 ON 28 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:07:34 ON 28 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

DICTIONARY FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

\*\*\* YOU HAVE NEW MAIL \*\*\*

=>


Uploading C:\Program Files\Stnexp\Queries\107306434.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full  
FULL SEARCH INITIATED 10:07:56 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 394 TO ITERATE

100.0% PROCESSED 394 ITERATIONS 8 ANSWERS  
SEARCH TIME: 00.00.01

L2 8 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 155.42 155.63

FILE 'CAPLUS' ENTERED AT 10:08:01 ON 28 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Dec 2004 VOL 142 ISS 1  
FILE LAST UPDATED: 24 Dec 2004 (20041224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2  
L3 6 L2

=> d l3 bib abs histr 1-6  
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;



SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)

STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels  
 IALL ----- ALL, indented with text labels  
 IBIB ----- BIB, indented with text labels  
 IMAX ----- MAX, indented with text labels  
 ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)  
 OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms  
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
                   containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 HITSEQ ----- HIT RN, its text modification, its CA index name, its  
                   structure diagram, plus NTE and SEQ fields  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its  
                   structure diagram, plus NTE and SEQ fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):bib

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1995:871986 CAPLUS  
 DN 123:314400  
 TI Preparation of fused pyrimidine derivatives as fluorescence-labeled  
       binding partners for oligodeoxyribonucleotides  
 IN Matteucci, Mark D.; Jones, Robert J.; Lin, Kuei-Ying  
 PA Gilead Sciences, Inc., USA  
 SO PCT Int. Appl., 75 pp.  
    CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9507918	A2	19950323	WO 1994-US10536	19940916
	WO 9507918	A3	19950803		
	W: JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5502177	A	19960326	US 1993-123505	19930917

EP 719272	A1	19960703	EP 1994-929830	19940916
EP 719272	B1	20030507		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09506859	T2	19970708	JP 1994-509393	19940916
AT 239752	E	20030515	AT 1994-929830	19940916
US 6005096	A	19991221	US 1995-436991	19950508
US 5763588	A	19980609	US 1995-481719	19950607
US 6617437	B1	20030909	US 1999-468454	19991221
US 2003207824	A1	20031106	US 2002-294066	20021114
PRAI US 1993-123505	A	19930917		
WO 1994-US10536	W	19940916		
US 1995-436991	A1	19950508		
US 1999-468454	A1	19991221		
OS	MARPAT-123:314400			

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1995:759132 CAPLUS  
DN 124:146760  
TI Oligonucleotide analogs containing unsaturated 3',5' and 2',5' allyl ether and allyl sulfide linkages capable of hybridizing to target nucleic acid sequences  
IN Matteucci, Mark D.; Cao, Xiaodong  
PA Gilead Sciences, Inc., USA  
SO U.S., 77 pp. Cont.-in-part of U.S. Ser. No. 892,902.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5434257	A	19950718	US 1993-142785	19931026
	US 5817781	A	19981006	US 1992-892902	19920601
	AT 174599	E	19990115	AT 1993-915177	19930601
	WO 9511911	A1	19950504	WO 1994-US12202	19941025
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6410702	B1	20020625	US 1998-165883	19981002
	US 2003120050	A1	20030626	US 2002-176763	20020621
	US 6683166	B2	20040127		
PRAI	US 1992-892902	A2	19920601		
	US 1993-142785	A	19931026		
	US 1998-165883	A1	19981002		
OS	MARPAT 124:146760				

L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1995:631025 CAPLUS  
DN 123:74138  
TI Substrate specificities of mitochondrial thymidine kinase and cytosolic deoxycytidine kinase against 5-aryl substituted pyrimidine-2'-deoxyribose analogs  
AU Eriksson, Staffan; Wang, Jianghai; Gronowitz, Salo; Johansson, Nils Gunnar  
CS Department Veterinary Medical Chemistry, Swedish University Agricultural Sciences, Uppsala, S-75123, Swed.  
SO Nucleosides & Nucleotides (1995), 14(3-5), 507-10  
CODEN: NUNUD5; ISSN: 0732-8311  
PB Dekker  
DT Journal  
LA English

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1992:531487 CAPLUS  
DN 117:131487

TI Synthesis and antiviral activity of various 5-substituted 2'-deoxyuridines and -cytidines  
 AU Peters, Dan; Hoernfeldt, Anna Britta; Gronowitz, Salo; Johansson, Nils Gunnar  
 CS Chem. Cent., Lund, S-221 00, Swed.  
 SO Nucleosides & Nucleotides (1992), 11(6), 1151-73  
 CODEN: NUNUD5; ISSN: 0732-8311  
 DT Journal  
 LA English

L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:235778 CAPLUS

DN 112:235778

TI Preparation of pyrimidine nucleosides as virucides and their intermediates  
 IN Johansson, K. Nils Gunnar; Malmberg, Hans C. G.; Noreen, Rolf; Sahlberg, S. Christer; Sohn, Daniel D.; Gronowitz, Salo

PA Medivir AB, Swed.

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8912061	A1	19891214	WO 1989-SE322	19890607
	W: AU, DK, FI, HU, JP, KR, NO, US				
	CA 1339313	A1	19970819	CA 1989-601897	19890606
	AU 8937504	A1	19900105	AU 1989-37504	19890607
	AU 637574	B2	19930603		
	EP 357571	A2	19900307	EP 1989-850184	19890607
	EP 357571	A3	19900613		
	EP 357571	B1	19960403		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03504969	T2	19911031	JP 1989-506227	19890607
	JP 2851094	B2	19990127		
	HU 57230	A2	19911128	HU 1989-4340	19890607
	HU 211736	B	19951228		
	EP 691333	A2	19960110	EP 1995-113626	19890607
	EP 691333	A3	19960214		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 136308	E	19960415	AT 1989-850184	19890607
	ES 2087090	T3	19960716	ES 1989-850184	19890607
	NO 9005300	A	19910206	NO 1990-5300	19901207
	NO 175981	B	19941003		
	NO 175981	C	19950111		
	DK 9002918	A	19910207	DK 1990-2918	19901207
	FI 94643	B	19950630	FI 1990-6053	19901207
	FI 94643	C	19951010		
	US 5440040	A	19950808	US 1991-613900	19910118
	US 5576429	A	19961119	US 1995-395877	19950228
PRAI	SE 1988-2173	A	19880610		
	EP 1989-850184	A3	19890607		
	WO 1989-SE322	A	19890607		
	US 1991-613900	A3	19910118		
OS	MARPAT 112:235778				

L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1986:130206 CAPLUS

DN 104:130206

TI Diels-Alder reactions of azadienes. A facile approach to the synthesis of pyridine- and pyridazine-substituted pyrimidine nucleosides

AU Maggiora, Linda; Mertes, Mathias P.

CS Dep. Med. Chem., Univ. Kansas, Lawrence, KS, 66045, USA  
SO Journal of Organic Chemistry (1986), 51(6), 950-1  
CODEN: JOCEAH; ISSN: 0022-3263  
DT Journal  
LA English  
OS CASREACT 104:130206

=>

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 10:09:39 ON 28 DEC 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:09:46 ON 28 DEC 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

DICTIONARY FILE UPDATES: 26 DEC 2004 HIGHEST RN 802853-20-9

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

\*\*\* YOU HAVE NEW MAIL \*\*\*

=>


Uploading C:\Program Files\Stnexp\Queries\107306435.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full  
FULL SEARCH INITIATED 10:10:12 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1070 TO ITERATE

100.0% PROCESSED 1070 ITERATIONS  
SEARCH TIME: 00.00.01

7 ANSWERS

L2 7 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
155.42	155.63

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:10:16 ON 28 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Dec 2004 VOL 142 ISS 1  
FILE LAST UPDATED: 24 Dec 2004 (20041224/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2  
L3 4 L2

=> d l3 bib abs hitstr 1-4

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1995:631025 CAPLUS  
DN 123:74138  
TI Substrate specificities of mitochondrial thymidine kinase and cytosolic deoxycytidine kinase against 5-aryl substituted pyrimidine-2'-deoxyribose analogs  
AU Eriksson, Staffan; Wang, Jianghai; Gronowitz, Salo; Johansson, Nils Gunnar  
CS Department Veterinary Medical Chemistry, Swedish University Agricultural Sciences, Uppsala, S-75123, Swed.  
SO Nucleosides & Nucleotides (1995), 14(3-5), 507-10  
CODEN: NUNUD5; ISSN: 0732-8311  
PB Dekker  
DT Journal  
LA English  
AB Some 5-aryl-2'-deoxyuridine and -deoxycytidine analogs, many with known antiviral activity, were evaluated as substrates for pure deoxycytidine kinase (dCK) and pure mitochondrial thymidine kinase (TK2). Some of the deoxyuridine compds. were also tested with pure cytosolic thymidine kinase (TK1). TK2 showed the highest phosphorylation activity with this type of

analogs.

IT 143325-21-7


RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(substrate specificities of cytosolic and mitochondrial thymidine kinase and cytosolic deoxycytidine kinase against 5-aryl substituted pyrimidine-2'-deoxyribose analogs)

RN 143325-21-7 CAPLUS

CN Cytidine, 2'-deoxy-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:531487 CAPLUS

DN 117:131487

TI Synthesis and antiviral activity of various 5-substituted 2'-deoxyuridines and -cytidines

AU Peters, Dan; Hoernfeldt, Anna Britta; Gronowitz, Salo; Johansson, Nils Gunnar

CS Chem. Cent., Lund, S-221 00, Swed.

SO Nucleosides & Nucleotides (1992), 11(6), 1151-73

CODEN: NUNUD5; ISSN: 0732-8311

DT Journal

LA English

AB 5-Cyclopropyl-2'-deoxycytidine and some 5-aryl-2'-deoxyuridines and -cytidines have been prepared and their inhibition of HIV have been tested.


IT 143324-95-2P 143324-96-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and deblocking of)

RN 143324-95-2 CAPLUS


CN 2(1H)-Pyrimidinone, 4-amino-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143324-96-3 CAPLUS  
CN Cytidine, 2'-deoxy-5-(4-pyridinyl)-, 3',5'-bis(4-methylbenzoate) (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




IT 143325-20-6P 143325-21-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 143325-20-6 CAPLUS  
CN 2(1H)-Pyrimidinone, 4-amino-1-(2-deoxy- $\alpha$ -D-erythro-pentofuranosyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143325-21-7 CAPLUS  
CN Cytidine, 2'-deoxy-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 1990:235778 CAPLUS  
DN 112:235778  
TI Preparation of pyrimidine nucleosides as virucides and their intermediates  
IN Johansson, K. Nils Gunnar; Malmberg, Hans C. G.; Noreen, Rolf; Sahlberg,



S. Christer; Sohn, Daniel D.; Gronowitz, Salo  
 PA Medivir AB, Swed.  
 SO PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8912061	A1	19891214	WO 1989-SE322	19890607
	W: AU, DK, FI, HU, JP, KR, NO, US				
	CA 1339313	A1	19970819	CA 1989-601897	19890606
	AU 8937504	A1	19900105	AU 1989-37504	19890607
	AU 637574	B2	19930603		
	EP 357571	A2	19900307	EP 1989-850184	19890607
	EP 357571	A3	19900613		
	EP 357571	B1	19960403		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03504969	T2	19911031	JP 1989-506227	19890607
	JP 2851094	B2	19990127		
	HU 57230	A2	19911128	HU 1989-4340	19890607
	HU 211736	B	19951228		
	EP 691333	A2	19960110	EP 1995-113626	19890607
	EP 691333	A3	19960214		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 136308	E	19960415	AT 1989-850184	19890607
	ES 2087090	T3	19960716	ES 1989-850184	19890607
	NO 9005300	A	19910206	NO 1990-5300	19901207
	NO 175981	B	19941003		
	NO 175981	C	19950111		
	DK 9002918	A	19910207	DK 1990-2918	19901207
	FI 94643	B	19950630	FI 1990-6053	19901207
	FI 94643	C	19951010		
	US 5440040	A	19950808	US 1991-613900	19910118
	US 5576429	A	19961119	US 1995-395877	19950228
PRAI	SE 1988-2173	A	19880610		
	EP 1989-850184	A3	19890607		
	WO 1989-SE322	A	19890607		
	US 1991-613900	A3	19910118		
OS	MARPAT 112:235778				
GI					



AB The title compds. [I; R1 = OH, NH2; R2 = (hetero)aryl, e.g. Q-Q2; X = O, S, Se, (un)substituted NH; R3 = H, OH, F, OMe; R4 = H, F, OH or its ether or ester residue, OMe, cyano, C.tplbond.CH, N3; R5 = OH or its ether or ester residue, (CH2)nP(O)(OM)2, (CH2)nP(O)(OM)CH2P(O)(OM)2; R6 = H, straight or branched C1-10 alkyl, halo, etc.; M = H, a pharmaceutically acceptable counterion; n = 0, 1], useful for treatment of infections by viruses requiring reverse transcriptase for replication, e.g. human immunodeficiency virus (HIV) and hepatitis B virus, were prepared. Thus, silylation of 5-(2-thienyl)uracil (II) with hexamethyldisilazane in the presence of Me3SiCl and (NH4)2SO4 under reflux gave bis-trimethylsilylated II which was stirred overnight with 2-deoxy-3,5-di-O-p-toluoyl-D-ribofuranosyl chloride in ClCH2CH2Cl in the presence of mol. sieve 4A. The product was treated with MeONa in MeOH to give  $\alpha$ - and  $\beta$ -I (R1 = R4 = R5 = OH, R2 = 2-thienyl, R3 = H).  $\alpha$ -I in vitro showed IC50 of 0.05-10  $\mu$ M against HIV in H9 cells. Analogously prepared and tested were addnl. 26 I. Cellular toxicity of I on H9 and F500 cells and inhibition of enzymes (e.g. HIV reverse transcriptase, hepatitis B virus DNA polymerase, and herpes simplex virus type 2 DNA polymerase) by I were also given.

IT **127235-51-2P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of pyrimidine nucleoside virucide)

RN 127235-51-2 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)- $\alpha$ -D-erythro-pentofuranosyl]-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **127235-71-6P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of, as virucide)


RN 127235-71-6 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy- $\alpha$ -D-erythro-pentofuranosyl)-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1986:130206 CAPLUS  
 DN 104:130206  
 TI Diels-Alder reactions of azadienes. A facile approach to the synthesis of pyridine- and pyridazine-substituted pyrimidine nucleosides  
 AU Maggiora, Linda; Mertes, Mathias P.  
 CS Dep. Med. Chem., Univ. Kansas, Lawrence, KS, 66045, USA  
 SO Journal of Organic Chemistry (1986), 51(6), 950-1  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA English  
 OS CASREACT 104:130206  
 GI



AB The Diels-Alder reaction of 5-ethynyl-2'-deoxyuridine I (R = H, Ac) with carboxylate II (R1 = Me; X = N) afforded 5-(3,6-dicarbomethoxypyridazin-4-yl)-2'-deoxyuridine III (R1 = Me, X = N) in 70% yield. Treatment of I with II (R1 = Et; X = X1 = CCO2Et) produced a 30% yield of III (R1 = Et; X = N, CCO2Et, X = CCO2Et, X1 = N).


IT 100021-03-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 100021-03-2 CAPLUS

CN 2,3,6-Pyridinetricarboxylic acid, 4-[1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidinyl]-, triethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>